Table 2: Historical MIPS Quality Measure Benchmark Results; created using PY2018 data and PY2020 Eligibility Rules,,,,,,,,,,,,,,,,,
Measure_Name,Measure_ID,Collection_Type,Measure_Type,High_Priority, Benchmark,Standard_Deviation,Average,Decile_3,Decile_4,Decile_5,Decile_6,Decile_7,Decile_8,Decile_9,Decile_10,TOPPED_OUT,SevenPointCap
Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%),1,eCQM,Intermediate Outcome,Y,,45.65,>= 99.46,99.45 - 92.62,92.61 - 74.48,74.47 - 59.09,59.08 - 46.85,46.84 - 37.89,37.88 - 31.41,<= 31.40,N,N,Y
Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%),1,Medicare Part B Claims,Intermediate Outcome,Y,,--,79.99-70.01,70 - 60.01,60 - 50.01,50 - 40.01,40 - 30.01,30 - 20.01,20 - 10.01,<= 10,N,N,Y
Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) or Angiotensin Receptor-Neprilysin Inhibitor (ARNI) Therapy for Left Ventricular Systolic Dysfunction (LVSD),5,eCQM,Process,Y,,78.133,21.9 - 59.57,59.58 - 71.5,71.51 - 80.47,80.48 - 87.86,87.87 - 95.22,95.23 - 99.99,--,100,N,N,N
Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) or Angiotensin Receptor-Neprilysin Inhibitor (ARNI) Therapy for Left Ventricular Systolic Dysfunction (LVSD),5,MIPS CQM,Process,Y,,88.665,45.19 - 68.5,68.51 - 82.34,82.35 - 94.34,94.35 - 99.99,--,--,--,100,N,N,N
Coronary Artery Disease (CAD): Antiplatelet Therapy,6,MIPS CQM,Process,Y,,89.163,11.82 - 74.75,74.76 - 86.37,86.38 - 93.74,93.75 - 98.62,98.63 - 99.99,--,--,100,N,N,N
Coronary Artery Disease (CAD): Beta-Blocker Therapy - Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF < 40%),7,eCQM,Process,Y,,84.225,37.83 - 70.77,70.78 - 80.45,80.46 - 86.72,86.73 - 91.65,91.66 - 95.37,95.38 - 97.12,97.13 - 99.99,100,N,N,N
Coronary Artery Disease (CAD): Beta-Blocker Therapy - Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF < 40%),7,MIPS CQM,Process,Y,,91.905,60.6 - 82.74,82.75 - 89.34,89.35 - 94.18,94.19 - 97.7,97.71 - 99.99,--,--,100,N,N,N
Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD),8,eCQM,Process,Y,,85.594,27.53 - 69.99,70 - 81.58,81.59 - 89.54,89.55 - 94.32,94.33 - 97.21,97.22 - 99.99,--,100,N,N,N
Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD),8,MIPS CQM,Process,Y,,94.663,61.82 - 85.7,85.71 - 92.74,92.75 - 97.23,97.24 - 99.99,--,--,--,100,Y,Y,N
Anti-Depressant Medication Management,9,eCQM,Process,Y,,50.754,2.55 - 18.4,18.41 - 32.53,32.54 - 49.34,49.35 - 64.59,64.6 - 90.11,90.12 - 93.07,93.08 - 98.96,>=98.97,N,N,N
Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation,12,Medicare Part B Claims,Process,Y,,97.842,52.58 - 97.35,97.36 - 99.99,--,--,--,--,--,100,Y,Y,N
Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation,12,eCQM,Process,Y,,86.905,2.93 - 66.65,66.66 - 84.72,84.73 - 93.9,93.91 - 98.25,98.26 - 99.69,99.7 - 99.99,--,100,N,N,N
Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation,12,MIPS CQM,Process,Y,,94.601,28.48 - 84.48,84.49 - 96.96,96.97 - 99.99,--,--,--,--,100,Y,Y,N
Age-Related Macular Degeneration (AMD): Dilated Macular Examination,14,Medicare Part B Claims,Process,Y,,96.175,27.65 - 92.46,92.47 - 99.99,--,--,--,--,--,100,Y,Y,N
Age-Related Macular Degeneration (AMD): Dilated Macular Examination,14,MIPS CQM,Process,Y,,87.535,3.45 - 60.77,60.78 - 86.91,86.92 - 96.92,96.93 - 99.9,99.91 - 99.99,--,--,100,Y,Y,N
Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care,19,eCQM,Process,Y,,76.858,2.79 - 35.53,35.54 - 65.4,65.41 - 86.49,86.5 - 96.65,96.66 - 99.87,99.88 - 99.99,--,100,N,N,Y
Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care,19,MIPS CQM,Process,Y,,84.598,3.12 - 38.76,38.77 - 82.7,82.71 - 98.63,98.64 - 99.99,--,--,--,100,Y,Y,Y
Perioperative Care: Selection of Prophylactic Antibiotic - First OR Second-Generation Cephalosporin,21,Medicare Part B Claims,Process,Y,,94.514,6.46 - 94.6,94.61 - 99.99,--,--,--,--,--,100,Y,Y,Y
Perioperative Care: Selection of Prophylactic Antibiotic - First OR Second-Generation Cephalosporin,21,MIPS CQM,Process,Y,,89.51,0.43 - 57.08,57.09 - 97.53,97.54 - 99.99,--,--,--,--,100,Y,Y,Y
Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients),23,Medicare Part B Claims,Process,Y,,94.942,2.92 - 98.63,98.64 - 99.99,--,--,--,--,--,100,Y,Y,Y
Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients),23,MIPS CQM,Process,Y,,92.717,0.95 - 79.83,79.84 - 98.51,98.52 - 99.99,--,--,--,--,100,Y,Y,Y
Communication with the Physician or Other Clinician Managing On-Going Care Post-Fracture for Men and Women Aged 50 Years and Older,24,Medicare Part B Claims,Process,Y,,88.571,3.74 - 61.49,61.5 - 92.14,92.15 - 99.34,99.35 - 99.99,--,--,--,100,Y,Y,Y
Communication with the Physician or Other Clinician Managing On-Going Care Post-Fracture for Men and Women Aged 50 Years and Older,24,MIPS CQM,Process,Y,,67.242,2.48 - 12.88,12.89 - 45.44,45.45 - 76.96,76.97 - 98.44,98.45 - 99.99,--,--,100,N,N,Y
Screening for Osteoporosis for Women Aged 65-85 Years of Age,39,Medicare Part B Claims,Process,Y,,57.614,3.19 - 23.84,23.85 - 41.8,41.81 - 56.96,56.97 - 74.39,74.4 - 93.49,93.5 - 99.37,99.38 - 99.99,100,N,N,N
Screening for Osteoporosis for Women Aged 65-85 Years of Age,39,MIPS CQM,Process,Y,,47.917,0.28 - 3,3.01 - 16.2,16.21 - 48.65,48.66 - 76.99,77 - 94.42,94.43 - 99.53,99.54 - 99.99,100,N,N,N
Coronary Artery Bypass Graft (CABG): Preoperative Beta-Blocker in Patients with Isolated CABG Surgery,44,MIPS CQM,Process,Y,,96.881,58.73 - 91.73,91.74 - 97.55,97.56 - 99.99,--,--,--,--,100,Y,Y,N
Advance Care Plan,47,Medicare Part B Claims,Process,Y,,79.95,0.65 - 18.17,18.18 - 74.86,74.87 - 98.73,98.74 - 99.99,--,--,--,100,Y,Y,Y
Advance Care Plan,47,MIPS CQM,Process,Y,,66.531,0.14 - 4.07,4.08 - 36.14,36.15 - 82.83,82.84 - 98.27,98.28 - 99.99,--,--,100,N,N,Y
Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older,48,Medicare Part B Claims,Process,Y,,64.209,0.33 - 1.28,1.29 - 5.02,5.03 - 98.41,98.42 - 99.99,--,--,--,100,Y,Y,N
Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older,48,MIPS CQM,Process,Y,,64.887,0.43 - 4.19,4.2 - 28.34,28.35 - 79.24,79.25 - 99.12,99.13 - 99.99,--,--,100,N,N,N
Urinary Incontinence: Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older,50,Medicare Part B Claims,Process,Y,,92.795,19.04 - 65.53,65.54 - 96.76,96.77 - 99.99,--,--,--,--,100,Y,Y,Y
Urinary Incontinence: Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older,50,MIPS CQM,Process,Y,,71.373,3.56 - 25.64,25.65 - 54.01,54.02 - 79.15,79.16 - 96.28,96.29 - 99.99,--,--,100,N,N,Y
Chronic Obstructive Pulmonary Disease (COPD): Long-Acting Inhaled Bronchodilator Therapy,52,Medicare Part B Claims,Process,Y,,97.329,44.62 - 93.26,93.27 - 99.99,--,--,--,--,--,100,Y,Y,N
Chronic Obstructive Pulmonary Disease (COPD): Long-Acting Inhaled Bronchodilator Therapy,52,MIPS CQM,Process,Y,,87.214,36.47 - 62.49,62.5 - 79.3,79.31 - 97.49,97.5 - 99.99,--,--,--,100,Y,Y,N
Appropriate Treatment for Children with Upper Respiratory Infection (URI),65,eCQM,Process,Y,,89.323,25.66 - 75.93,75.94 - 86.79,86.8 - 93.39,93.4 - 97.04,97.05 - 99.99,--,--,100,N,N,Y
Appropriate Treatment for Children with Upper Respiratory Infection (URI),65,MIPS CQM,Process,Y,,95.76,59.39 - 89.07,89.08 - 94.61,94.62 - 98.71,98.72 - 99.99,--,--,--,100,Y,Y,Y
Appropriate Testing for Children with Pharyngitis,66,eCQM,Process,Y,,66.7,0.51 - 17.69,17.7 - 53.71,53.72 - 77.03,77.04 - 87.68,87.69 - 93.53,93.54 - 95.82,95.83 - 99.99,100,N,N,Y
Appropriate Testing for Children with Pharyngitis,66,MIPS CQM,Process,Y,,78.138,19.27 - 56.16,56.17 - 69.59,69.6 - 81.97,81.98 - 91.38,91.39 - 95.99,96 - 98.17,98.18 - 99.99,100,N,N,Y
Hematology: Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow,67,MIPS CQM,Process,Y,,55.309,3.67 - 8.57,8.58 - 23.25,23.26 - 47.49,47.5 - 99.77,99.78 - 99.99,--,--,100,N,N,N
Hematology: Multiple Myeloma: Treatment with Bisphosphonates,69,MIPS CQM,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Hematology: Chronic Lymphocytic Leukemia (CLL): Baseline Flow Cytometry,70,MIPS CQM,Process,Y,,52.319,2.82 - 6.96,6.97 - 10.7,10.71 - 45.44,45.45 - 98.74,98.75 - 99.99,--,--,100,N,N,N
Prevention of Central Venous Catheter (CVC) - Related Bloodstream Infections,76,Medicare Part B Claims,Process,Y,,95.755,12.38 - 91.82,91.83 - 99.99,--,--,--,--,--,100,Y,Y,Y
Prevention of Central Venous Catheter (CVC) - Related Bloodstream Infections,76,MIPS CQM,Process,Y,,95.223,20.21 - 89.62,89.63 - 97.91,97.92 - 99.99,--,--,--,--,100,Y,Y,Y
Acute Otitis Externa (AOE): Systemic Antimicrobial Therapy - Avoidance of Inappropriate Use,93,Medicare Part B Claims,Process,Y,,93.69,18.37 - 94.81,94.82 - 99.99,--,--,--,--,--,100,Y,Y,Y
Acute Otitis Externa (AOE): Systemic Antimicrobial Therapy - Avoidance of Inappropriate Use,93,MIPS CQM,Process,Y,,90.857,41.46 - 73.9,73.91 - 86.94,86.95 - 95.82,95.83 - 99.99,--,--,--,100,Y,N,Y
Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients,102,eCQM,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients,102,MIPS CQM,Process,Y,,96.141,41.44 - 92.48,92.49 - 99.99,--,--,--,--,--,100,Y,N,Y
Prostate Cancer: Combination Androgen Deprivation Therapy for High Risk or Very High Risk Prostate Cancer,104,MIPS CQM,Process,Y,,89.334,25.51 - 61.5,61.51 - 92.34,92.35 - 98.47,98.48 - 99.99,--,--,--,100,Y,N,N
Adult Major Depressive Disorder (MDD): Suicide Risk Assessment,107,eCQM,Process,Y,,39.287,0.05 - 0.74,0.75 - 5.18,5.19 - 30.29,30.3 - 72.9,72.91 - 96.13,96.14 - 99.11,99.12 - 99.99,100,N,N,N
Preventive Care and Screening: Influenza Immunization,110,Medicare Part B Claims,Process,Y,,64.746,1.1 - 16.14,16.15 - 34.76,34.77 - 72.83,72.84 - 98.82,98.83 - 99.99,--,--,100,N,N,N
Preventive Care and Screening: Influenza Immunization,110,eCQM,Process,Y,,39.641,0.11 - 3.34,3.35 - 16.95,16.96 - 36.49,36.5 - 58.4,58.41 - 81.09,81.1 - 92.41,92.42 - 99.99,100,N,N,N
Preventive Care and Screening: Influenza Immunization,110,MIPS CQM,Process,Y,,58.519,0.21 - 11.43,11.44 - 32.82,32.83 - 61.63,61.64 - 88.07,88.08 - 99.43,99.44 - 99.99,--,100,N,N,N
Pneumococcal Vaccination Status for Older Adults,111,Medicare Part B Claims,Process,Y,,74.898,1.05 - 40.69,40.7 - 61.56,61.57 - 81.1,81.11 - 95.37,95.38 - 99.99,--,--,100,N,N,N
Pneumococcal Vaccination Status for Older Adults,111,eCQM,Process,Y,,49.644,0.15 - 4.44,4.45 - 24.15,24.16 - 52.06,52.07 - 75.22,75.23 - 88.81,88.82 - 95.03,95.04 - 99.99,100,N,N,N
Pneumococcal Vaccination Status for Older Adults,111,MIPS CQM,Process,Y,,61.177,0.35 - 13.78,13.79 - 43.43,43.44 - 68.79,68.8 - 82.12,82.13 - 93.74,93.75 - 99.37,99.38 - 99.99,100,N,N,N
Breast Cancer Screening,112,Medicare Part B Claims,Process,Y,,71.062,3.12 - 28.63,28.64 - 57.13,57.14 - 75.93,75.94 - 94.96,94.97 - 99.99,--,--,100,N,N,N
Breast Cancer Screening,112,eCQM,Process,Y,,48.351,0.28 - 7.3,7.31 - 27.28,27.29 - 51.55,51.56 - 69.35,69.36 - 81.47,81.48 - 88.26,88.27 - 98.54,>=98.55,N,N,N
Breast Cancer Screening,112,MIPS CQM,Process,Y,,52.881,0.43 - 7.55,7.56 - 27.87,27.88 - 55.69,55.7 - 77.55,77.56 - 92.63,92.64 - 99.99,--,100,N,N,N
Colorectal Cancer Screening,113,MIPS CQM,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Colorectal Cancer Screening,113,Medicare Part B Claims,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Colorectal Cancer Screening,113,eCQM,Process,Y,,45.049,0.13 - 2.58,2.59 - 19.33,19.34 - 45.63,45.64 - 70,70.01 - 84.49,84.5 - 90.81,90.82 - 99.38,>=99.39,N,N,N
Avoidance of Antibiotic Treatment in Adults With Acute Bronchitis,116,MIPS CQM,Process,Y,,74.363,6.61 - 37.49,37.5 - 55.3,55.31 - 81.48,81.49 - 98.71,98.72 - 99.99,--,--,100,N,N,Y
Diabetes: Eye Exam,117,Medicare Part B Claims,Process,Y,,85.244,3.32 - 25.79,25.8 - 91.04,91.05 - 99.99,--,--,--,--,100,Y,Y,N
Diabetes: Eye Exam,117,eCQM,Process,Y,,55.494,0.6 - 6.83,6.84 - 21.2,21.21 - 49.99,50 - 97.37,97.38 - 99.84,99.85 - 99.99,--,100,N,N,N
Diabetes: Eye Exam,117,MIPS CQM,Process,Y,,82.021,0.61 - 23.29,23.3 - 80.68,80.69 - 97.83,97.84 - 99.99,--,--,--,100,Y,Y,N
Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy - Diabetes or Left Ventricular Systolic Dysfunction (LVEF < 40%),118,MIPS CQM,Process,Y,,83.238,34.59 - 71.41,71.42 - 77.79,77.8 - 84.1,84.11 - 89.81,89.82 - 97.46,97.47 - 99.99,--,100,N,N,N
Diabetes: Medical Attention for Nephropathy,119,eCQM,Process,Y,,78.398,4.17 - 53.56,53.57 - 71.41,71.42 - 83.46,83.47 - 92,92.01 - 97.94,97.95 - 99.63,99.64 - 99.99,100,N,N,N
Diabetes: Medical Attention for Nephropathy,119,MIPS CQM,Process,Y,,82.642,5.77 - 57.86,57.87 - 77.14,77.15 - 87.32,87.33 - 98.18,98.19 - 99.99,--,--,100,N,N,N
"Diabetes Mellitus: Diabetic Foot and Ankle Care, Peripheral Neuropathy - Neurological Evaluation",126,MIPS CQM,Process,Y,,77.971,0.58 - 26.79,26.8 - 66.61,66.62 - 91.69,91.7 - 99.99,--,--,--,100,N,N,N
"Diabetes Mellitus: Diabetic Foot and Ankle Care, Ulcer Prevention - Evaluation of Footwear",127,MIPS CQM,Process,Y,,75.94,0.48 - 22.58,22.59 - 58.66,58.67 - 89.92,89.93 - 99.99,--,--,--,100,N,N,N
Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan,128,Medicare Part B Claims,Process,Y,,81.113,15.33 - 32.59,32.6 - 64.33,64.34 - 99.07,99.08 - 99.99,--,--,--,100,Y,Y,N
Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan,128,eCQM,Process,Y,,47.589,0.42 - 17.47,17.48 - 23.88,23.89 - 37.38,37.39 - 73.96,73.97 - 94.14,94.15 - 98.35,98.36 - 99.99,100,N,N,N
Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan,128,MIPS CQM,Process,Y,,70.579,4.22 - 22.9,22.91 - 40.99,41 - 83.85,83.86 - 98.35,98.36 - 99.99,--,--,100,N,N,N
Documentation of Current Medications in the Medical Record,130,Medicare Part B Claims,Process,Y,,96.133,13.26 - 93.38,93.39 - 99.32,99.33 - 99.99,--,--,--,--,100,Y,Y,Y
Documentation of Current Medications in the Medical Record,130,eCQM,Process,Y,,89.126,6.46 - 66.01,66.02 - 88.81,88.82 - 97.34,97.35 - 99.68,99.69 - 99.99,--,--,100,Y,Y,Y
Documentation of Current Medications in the Medical Record,130,MIPS CQM,Process,Y,,87.813,3.07 - 43.67,43.68 - 94.64,94.65 - 99.68,99.69 - 99.99,--,--,--,100,Y,Y,Y
Preventive Care and Screening: Screening for Depression and Follow-Up Plan,134,Medicare Part B Claims,Process,Y,,72.648,0.17 - 0.88,0.89 - 45.49,45.5 - 99.54,99.55 - 99.99,--,--,--,100,Y,Y,N
Preventive Care and Screening: Screening for Depression and Follow-Up Plan,134,eCQM,Process,Y,,36.996,0.08 - 1.82,1.83 - 8.03,8.04 - 26.73,26.74 - 65.2,65.21 - 88.6,88.61 - 95.65,95.66 - 99.99,100,N,N,N
Preventive Care and Screening: Screening for Depression and Follow-Up Plan,134,MIPS CQM,Process,Y,,62.116,0.04 - 2.82,2.83 - 27.58,27.59 - 74.39,74.4 - 96.18,96.19 - 99.99,--,--,100,N,N,N
Melanoma: Continuity of Care - Recall System,137,MIPS CQM,Structure,Y,,90.938,3.95 - 67.31,67.32 - 95.29,95.3 - 99.99,--,--,--,--,100,N,N,Y
Melanoma: Coordination of Care,138,MIPS CQM,Process,Y,,81.008,2.13 - 25.6,25.61 - 72.16,72.17 - 99.99,--,--,--,--,100,Y,N,Y
Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% OR Documentation of a Plan of Care,141,Medicare Part B Claims,Outcome,Y,,97.727,37.12 - 96.6,96.61 - 99.99,--,--,--,--,--,100,N,N,Y
Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% OR Documentation of a Plan of Care,141,MIPS CQM,Outcome,Y,,43.786,0.29 - 9.15,9.16 - 17.45,17.46 - 26.65,26.66 - 82.02,82.03 - 99.96,99.97 - 99.99,--,100,N,N,Y
Oncology: Medical and Radiation - Pain Intensity Quantified,143,eCQM,Process,Y,,84.968,2.27 - 47.97,47.98 - 84.62,84.63 - 95.94,95.95 - 99.05,99.06 - 99.99,--,--,100,Y,Y,Y
Oncology: Medical and Radiation - Pain Intensity Quantified,143,MIPS CQM,Process,Y,,89.521,4.15 - 67.44,67.45 - 93.08,93.09 - 99.52,99.53 - 99.99,--,--,--,100,Y,Y,Y
Oncology: Medical and Radiation - Plan of Care for Pain,144,MIPS CQM,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Radiology: Exposure Dose Indices or Exposure Time and Number of Images Reported for Procedures Using Fluoroscopy,145,Medicare Part B Claims,Process,Y,,88.762,4.25 - 58.75,58.76 - 91.16,91.17 - 98.6,98.61 - 99.99,--,--,--,100,Y,Y,Y
Radiology: Exposure Dose Indices or Exposure Time and Number of Images Reported for Procedures Using Fluoroscopy,145,MIPS CQM,Process,Y,,86.713,3.3 - 47.44,47.45 - 86.44,86.45 - 98.56,98.57 - 99.99,--,--,--,100,Y,Y,Y
"Radiology: Inappropriate Use of ""Probably Benign"" Assessment Category in Screening Mammograms",146,Medicare Part B Claims,Process,Y,,0.253,4.15 - 0.5,0.49 - 0.19,0.18 - 0,--,--,--,--,0,Y,Y,Y
"Radiology: Inappropriate Use of ""Probably Benign"" Assessment Category in Screening Mammograms",146,MIPS CQM,Process,Y,,0.428,5.57 - 0.66,0.65 - 0.25,0.24 - 0.11,0.1 - 0.04,0.03 - 0,--,--,0,Y,Y,Y
Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy,147,Medicare Part B Claims,Process,Y,,90.374,12.11 - 61.89,61.9 - 92.29,92.3 - 99.99,--,--,--,--,100,Y,Y,Y
Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy,147,MIPS CQM,Process,Y,,93.418,29.25 - 77.36,77.37 - 95.22,95.23 - 99.99,--,--,--,--,100,Y,Y,Y
Falls: Risk Assessment,154,Medicare Part B Claims,Process,Y,,95.281,7.43 - 89.14,89.15 - 99.99,--,--,--,--,--,100,Y,Y,Y
Falls: Risk Assessment,154,MIPS CQM,Process,Y,,82.819,3.33 - 31.16,31.17 - 78.37,78.38 - 98.5,98.51 - 99.99,--,--,--,100,Y,Y,Y
Falls: Plan of Care,155,Medicare Part B Claims,Process,Y,,88.142,1.4 - 28.63,28.64 - 99.99,--,--,--,--,--,100,Y,Y,Y
Falls: Plan of Care,155,MIPS CQM,Process,Y,,79.155,1.94 - 26.71,26.72 - 70.1,70.11 - 94.78,94.79 - 99.99,--,--,--,100,N,N,Y
Coronary Artery Bypass Graft (CABG): Prolonged Intubation,164,MIPS CQM,Outcome,Y,,7.264,31.14 - 13.56,13.55 - 11.36,11.35 - 8.72,8.71 - 6.8,6.79 - 5.83,5.82 - 4.7,4.69 - 3.94 ,<= 3.93,N,N,Y
Coronary Artery Bypass Graft (CABG): Postoperative Renal Failure,167,MIPS CQM,Outcome,Y,,1.737,7.36 - 3.79,3.78 - 2.94,2.93 - 2.27,2.26 - 1.81,1.8 - 1.33,1.32 - 0.92,0.91 - 0,0,Y,Y,Y
Coronary Artery Bypass Graft (CABG): Surgical Re-Exploration,168,MIPS CQM,Outcome,Y,,2.476,10.93 - 5.93,5.92 - 4.08,4.07 - 3.24,3.23 - 2.31,2.3 - 1.79,1.78 - 1.23,1.22 - 0.9,<= 0.89,Y,Y,Y
Rheumatoid Arthritis (RA): Tuberculosis Screening,176,MIPS CQM,Process,Y,,74.488,2.04 - 27.93,27.94 - 52.79,52.8 - 89.14,89.15 - 99.99,--,--,--,100,N,N,N
Rheumatoid Arthritis (RA): Periodic Assessment of Disease Activity,177,MIPS CQM,Process,N,,--,--,--,--,--,--,--,--,100,N,N,N
Rheumatoid Arthritis (RA): Functional Status Assessment,178,MIPS CQM,Process,Y,,84.508,3.05 - 45.46,45.47 - 82.22,82.23 - 95.56,95.57 - 99.99,--,--,--,100,Y,Y,N
Rheumatoid Arthritis (RA): Glucocorticoid Management,180,MIPS CQM,Process,Y,,78.459,2.92 - 40.89,40.9 - 68.23,68.24 - 87.2,87.21 - 98.91,98.92 - 99.99,--,--,100,N,N,N
Elder Maltreatment Screen and Follow-Up Plan,181,Medicare Part B Claims,Process,Y,,86.21,0.25 - 12.19,12.2 - 99.48,99.49 - 99.99,--,--,--,--,100,Y,Y,Y
Elder Maltreatment Screen and Follow-Up Plan,181,MIPS CQM,Process,Y,,77.921,0.56 - 27.74,27.75 - 67.74,67.75 - 92.05,92.06 - 99.99,--,--,--,100,N,N,Y
Functional Outcome Assessment,182,Medicare Part B Claims,Process,Y,,92.703,0.21 - 88.9,88.91 - 99.93,99.94 - 99.99,--,--,--,--,100,Y,Y,Y
Functional Outcome Assessment,182,MIPS CQM,Process,Y,,54.454,0.18 - 1.38,1.39 - 5.66,5.67 - 87.12,87.13 - 99.66,99.67 - 99.99,--,--,100,N,N,Y
Colonoscopy Interval for Patients with a History of Adenomatous Polyps - Avoidance of Inappropriate Use,185,MIPS CQM,Process,Y,,80.575,1.6 - 27.26,27.27 - 71.75,71.76 - 98.03,98.04 - 99.99,--,--,--,100,Y,Y,Y
Stroke and Stroke Rehabilitation: Thrombolytic Therapy,187,MIPS CQM,Process,Y,,85.629,11.43 - 53.11,53.12 - 79.24,79.25 - 97.28,97.29 - 99.99,--,--,--,100,Y,Y,N
Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery,191,eCQM,Outcome,Y,,88.652,11.89 - 66.86,66.87 - 87.17,87.18 - 96.14,96.15 - 98.86,98.87 - 99.99,--,--,100,N,N,Y
Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery,191,MIPS CQM,Outcome,Y,,95.494,55.45 - 87.71,87.72 - 95.06,95.07 - 98.9,98.91 - 99.99,--,--,--,100,Y,Y,Y
Radiology: Stenosis Measurement in Carotid Imaging Reports,195,Medicare Part B Claims,Process,Y,,96.541,39.7 - 90.55,90.56 - 98.48,98.49 - 99.99,--,--,--,--,100,Y,Y,N
Radiology: Stenosis Measurement in Carotid Imaging Reports,195,MIPS CQM,Process,Y,,97.315,48.4 - 93.51,93.52 - 98.97,98.98 - 99.99,--,--,--,--,100,Y,Y,N
"HIV/AIDS: Sexually Transmitted Disease Screening for Chlamydia, Gonorrhea, and Syphilis",205,MIPS CQM,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Functional Status Change for Patients with Knee Impairments,217,MIPS CQM,Patient Reported Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Functional Status Change for Patients with Hip Impairments,218,MIPS CQM,Patient Reported Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
"Functional Status Change for Patients with Lower Leg, Foot or Ankle Impairments",219,MIPS CQM,Patient Reported Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Functional Status Change for Patients with Low Back Impairments,220,MIPS CQM,Patient Reported Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Functional Status Change for Patients with Shoulder Impairments,221,MIPS CQM,Patient Reported Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
"Functional Status Change for Patients with Elbow, Wrist or Hand Impairments",222,MIPS CQM,Patient Reported Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Radiology: Reminder System for Screening Mammograms,225,Medicare Part B Claims,Structure,Y,,96.742,3.45 - 99.16,99.17 - 99.99,--,--,--,--,--,100,N,N,Y
Radiology: Reminder System for Screening Mammograms,225,MIPS CQM,Structure,Y,,98.294,29.83 - 99.99,--,--,--,--,--,--,100,N,N,Y
Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention,226,Medicare Part B Claims,Process,Y,,98.139,66.66 - 95.85,95.86 - 99.29,99.3 - 99.99,--,--,--,--,100,Y,N,N
Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention,226,eCQM,Process,Y,,59.92,0.93 - 7.26,7.27 - 24.15,24.16 - 73.97,73.98 - 90.28,90.29 - 97.1,97.11 - 99.99,--,100,N,N,N
Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention,226,MIPS CQM,Process,Y,,60.355,1.88 - 10.45,10.46 - 25.48,25.49 - 65.69,65.7 - 97.66,97.67 - 99.99,--,--,100,N,N,N
Controlling High Blood Pressure,236,Medicare Part B Claims,Intermediate Outcome,Y,,72.531,20 - 29.99,30 - 39.99,40 - 49.99,50 - 59.99,60 - 69.99,70 - 79.99,80 - 89.99,>= 90,N,N,Y
Controlling High Blood Pressure,236,MIPS CQM,Intermediate Outcome,Y,,67.076,20 - 29.99,30 - 39.99,40 - 49.99,50 - 59.99,60 - 69.99,70 - 79.99,80 - 89.99,>= 90,N,N,Y
Controlling High Blood Pressure,236,eCQM,Intermediate Outcome,Y,,63.64,20 - 29.99,30 - 39.99,40 - 49.99,50 - 59.99,60 - 69.99,70 - 79.99,80 - 89.99,>= 90,N,N,Y
Use of High-Risk Medications in the Elderly,238,MIPS CQM,Process,Y,,2.687,27.17 - 13.48,13.47 - 8.52,8.51 - 2.18,2.17 - 0.34,0.33 - 0.01,--,--,0,Y,Y,Y
Use of High-Risk Medications in the Elderly,238,eCQM,Process,Y,,3.814,32.77  - 16.99,16.98 - 11.49,11.48 - 4.4,4.39 - 0.58,0.57 - 0.01,--,--,0,Y,Y,Y
Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents,239,eCQM,Process,Y,,39.227,0.46 - 21.78,21.79 - 29.34,29.35 - 33.32,33.33 - 43.69,43.7 - 71.49,71.5 - 85.53,85.54 - 99.39,>=99.4,N,N,N
Childhood Immunization Status,240,eCQM,Process,Y,,29.577,0.95 - 5.25,5.26 - 15.09,15.1 - 29.41,29.42 - 40.61,40.62 - 53.55,53.56 - 60.14,60.15 - 75.58,>=75.59,N,N,N
Cardiac Rehabilitation Patient Referral from an Outpatient Setting,243,MIPS CQM,Process,Y,,29.429,0.5 - 2.62,2.63 - 7.27,7.28 - 20.74,20.75 - 42.9,42.91 - 71.81,71.82 - 88.16,88.17 - 99.99,100,N,N,Y
Barrett's Esophagus,249,Medicare Part B Claims,Process,Y,,99.947,97.2 - 99.99,--,--,--,--,--,--,100,Y,Y,N
Barrett's Esophagus,249,MIPS CQM,Process,Y,,98.905,71.31 - 99.84,99.85 - 99.99,--,--,--,--,--,100,Y,Y,N
Radical Prostatectomy Pathology Reporting,250,Medicare Part B Claims,Process,Y,,99.909,98.1 - 99.99,--,--,--,--,--,--,100,Y,Y,N
Radical Prostatectomy Pathology Reporting,250,MIPS CQM,Process,Y,,99.545,98.78 - 99.99,--,--,--,--,--,--,100,Y,Y,N
Ultrasound Determination of Pregnancy Location for Pregnant Patients with Abdominal Pain,254,Medicare Part B Claims,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Ultrasound Determination of Pregnancy Location for Pregnant Patients with Abdominal Pain,254,MIPS CQM,Process,Y,,93.058,57.55 - 80.39,80.4 - 90.61,90.62 - 96.28,96.29 - 99.99,--,--,--,100,Y,N,N
Rate of Open Repair of Small or Moderate Non-Ruptured Infrarenal Abdominal Aortic Aneurysms (AAA) without Major Complications (Discharged to Home by Post-Operative Day #7),258,MIPS CQM,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Rate of Endovascular Aneurysm Repair (EVAR) of Small or Moderate Non-Ruptured Infrarenal Abdominal Aortic Aneurysms (AAA) without Major Complications (Discharged to Home by Post Operative Day #2),259,MIPS CQM,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
"Rate of Carotid Endarterectomy (CEA) for Asymptomatic Patients, without Major Complications (Discharged to Home by Post-Operative Day #2)",260,MIPS CQM,Outcome,Y,,89.101,29.83 - 85.11,85.12 - 88.16,88.17 - 91.93,91.94 - 97.12,97.13 - 99.99,--,--,100,N,N,Y
Referral for Otologic Evaluation for Patients with Acute or Chronic Dizziness,261,Medicare Part B Claims,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Referral for Otologic Evaluation for Patients with Acute or Chronic Dizziness,261,MIPS CQM,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Sentinel Lymph Node Biopsy for Invasive Breast Cancer,264,MIPS CQM,Process,Y,,98.59,89.01 - 95.33,95.34 - 98.59,98.6 - 99.99,--,--,--,--,100,Y,Y,N
Biopsy Follow-Up,265,MIPS CQM,Process,Y,,83.486,0.66 - 25.36,25.37 - 82.3,82.31 - 99.78,99.79 - 99.99,--,--,--,100,Y,Y,Y
Epilepsy: Counseling for Women of Childbearing Potential with Epilepsy,268,Medicare Part B Claims,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Epilepsy: Counseling for Women of Childbearing Potential with Epilepsy,268,MIPS CQM,Process,Y,,59.749,1.95 - 14.67,14.68 - 28.83,28.84 - 64.69,64.7 - 95.44,95.45 - 99.99,--,--,100,N,N,N
Inflammatory Bowel Disease (IBD): Assessment of Hepatitis B Virus (HBV) Status Before Initiating Anti-TNF (Tumor Necrosis Factor) Therapy,275,MIPS CQM,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Sleep Apnea: Severity Assessment at Initial Diagnosis,277,MIPS CQM,Process,Y,,70.686,0.36 - 5.68,5.69 - 38.82,38.83 - 90.61,90.62 - 99.99,--,--,--,100,N,N,N
Sleep Apnea: Assessment of Adherence to Positive Airway Pressure Therapy,279,MIPS CQM,Process,Y,,86.446,25.5 - 50.29,50.3 - 80.61,80.62 - 98.66,98.67 - 99.99,--,--,--,100,Y,Y,N
Dementia: Cognitive Assessment,281,eCQM,Process,Y,,48.351,0.51 - 3.56,3.57 - 10.27,10.28 - 43.86,43.87 - 87.33,87.34 - 98.51,98.52 - 99.99,--,100,N,N,N
Dementia: Functional Status Assessment,282,MIPS CQM,Process,Y,,79.756,0.85 - 28.15,28.16 - 70.57,70.58 - 96.65,96.66 - 99.99,--,--,--,100,Y,Y,N
Dementia Associated Behavioral and Psychiatric Symptoms Screening and Management,283,MIPS CQM,Process,Y,,87.772,7.78 - 52.44,52.45 - 89.75,89.76 - 99.76,99.77 - 99.99,--,--,--,100,Y,Y,N
Dementia: Safety Concern Screening and Follow-Up for Patients with Dementia,286,MIPS CQM,Process,Y,,77.21,5.2 - 19.55,19.56 - 56.03,56.04 - 98.28,98.29 - 99.99,--,--,--,100,Y,Y,Y
Dementia: Education and Support of Caregivers for Patients with Dementia,288,MIPS CQM,Process,Y,,72.104,3.48 - 15.72,15.73 - 44.87,44.88 - 86.83,86.84 - 99.99,--,--,--,100,N,N,Y
Parkinson's Disease: Psychiatric Symptoms Assessment for Patients with Parkinson's Disease,290,MIPS CQM,Process,Y,,58.069,3.5 - 9.37,9.38 - 22.94,22.95 - 51.84,51.85 - 99.99,--,--,--,100,N,N,N
Parkinson's Disease: Cognitive Impairment or Dysfunction Assessment for Patients with Parkinson's Disease,291,MIPS CQM,Process,Y,,75.281,1.77 - 10.78,10.79 - 56.4,56.41 - 99.99,--,--,--,--,100,Y,Y,N
Parkinson's Disease: Rehabilitative Therapy Options,293,MIPS CQM,Process,Y,,77.298,3.7 - 24.61,24.62 - 63.32,63.33 - 95.64,95.65 - 99.99,--,--,--,100,Y,Y,Y
Cataracts: Improvement in Patient's Visual Function within 90 Days Following Cataract Surgery,303,MIPS CQM,Patient Reported Outcome,Y,,66.37,1.98 - 26.35,26.36 - 42.92,42.93 - 69.96,69.97 - 96.72,96.73 - 99.99,--,--,100,N,N,Y
Cataracts: Patient Satisfaction within 90 Days Following Cataract Surgery,304,MIPS CQM,Patient Engagement/Experience,Y,,67.624,1.6 - 20.14,20.15 - 49.27,49.28 - 75.75,75.76 - 96.39,96.4 - 99.99,--,--,100,N,N,Y
Initiation and Engagement of Alcohol and Other Drug Dependence Treatment,305,eCQM,Process,Y,,3.685,0.08 - 0.36,0.37 - 0.64,0.65 - 1.43,1.44 - 3.33,3.34 - 8.02,8.03 - 12.36,12.37 - 39.07,>=39.08,N,N,Y
Cervical Cancer Screening,309,eCQM,Process,Y,,35.845,0.27 - 3.41,3.42 - 14.37,14.38 - 32.08,32.09 - 53.86,53.87 - 73.98,73.99 - 85.35,85.36 - 96.91,>=96.92,N,N,N
Chlamydia Screening for Women,310,eCQM,Process,Y,,35.749,0.91 - 6.88,6.89 - 19.03,19.04 - 35.12,35.13 - 50.59,50.6 - 66.53,66.54 - 72.12,72.13 - 82.47,>=82.48,N,N,N
Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented,317,Medicare Part B Claims,Process,Y,,78.153,4.32 - 29.34,29.35 - 55.77,55.78 - 95.57,95.58 - 99.99,--,--,--,100,Y,N,N
Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented,317,eCQM,Process,Y,,34.819,0.23 - 12.24,12.25 - 21.9,21.91 - 31.4,31.41 - 43.4,43.41 - 61.52,61.53 - 79.17,79.18 - 99.99,100,N,N,N
Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented,317,MIPS CQM,Process,Y,,57.812,0.26 - 16.39,16.4 - 33.22,33.23 - 53.73,53.74 - 91.5,91.51 - 99.99,--,--,100,N,N,N
Falls: Screening for Future Fall Risk,318,eCQM,Process,Y,,56.602,0.04 - 1.38,1.39 - 21.67,21.68 - 65.26,65.27 - 90.35,90.36 - 98.15,98.16 - 99.5,99.51 - 99.99,100,N,N,Y
Appropriate Follow-Up Interval for Normal Colonoscopy in Average Risk Patients,320,Medicare Part B Claims,Process,Y,,93.891,17.34 - 86.8,86.81 - 95.22,95.23 - 99.99,--,--,--,--,100,Y,Y,Y
Appropriate Follow-Up Interval for Normal Colonoscopy in Average Risk Patients,320,MIPS CQM,Process,Y,,86.428,1.02 - 59.13,59.14 - 85.38,85.39 - 95.09,95.1 - 99.07,99.08 - 99.99,--,--,100,Y,Y,Y
CAHPS for MIPs Clinician/Group Survey,321,Certified Survey Vendor,Patient Engagement/Experience,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Preoperative Evaluation in Low-Risk Surgery Patients,322,MIPS CQM,Efficiency,Y,,2.794,65.24 - 5.83 ,5.82 - 0.97,0.96 - 0.01,--,--,--,--,0,Y,Y,Y
Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Routine Testing After Percutaneous Coronary Intervention (PCI),323,MIPS CQM,Efficiency,Y,,3.081,77.03 - 4.87,4.86 - 0.68,0.67 - 0.01,--,--,--,--,0,Y,Y,Y
"Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Testing in Asymptomatic, Low-Risk Patients",324,MIPS CQM,Efficiency,Y,,5.898,55.83 - 30.16,30.15 - 20.9,20.89 - 2.78,2.77 - 0.01,--,--,--,0,Y,Y,Y
Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy,326,Medicare Part B Claims,Process,Y,,97.067,48.19 - 93.12,93.13 - 99.99,--,--,--,--,--,100,Y,Y,N
Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy,326,MIPS CQM,Process,Y,,87.757,22.05 - 68.06,68.07 - 79.5,79.51 - 95.03,95.04 - 99.99,--,--,--,100,Y,N,N
Adult Sinusitis: Antibiotic Prescribed for Acute Viral Sinusitis (Overuse),331,MIPS CQM,Process,Y,,44.816,100 - 97.36,97.35 - 87.13,87.12 - 76.08,76.07 - 65.57,65.56 - 54.28,54.27 - 43.59,43.58 - 34.32,<=34.31 ,N,N,Y
Adult Sinusitis: Appropriate Choice of Antibiotic: Amoxicillin With or Without Clavulanate Prescribed for Patients with Acute Bacterial Sinusitis (Appropriate Use),332,MIPS CQM,Process,Y,,88.326,15.68 - 58.19,58.2 - 87.82,87.83 - 98.07,98.08 - 99.99,--,--,--,100,Y,Y,Y
Adult Sinusitis: Computerized Tomography (CT) for Acute Sinusitis (Overuse),333,MIPS CQM,Efficiency,Y,,2.834,59.37 - 11.85,11.84 - 6.36,6.35 - 1.82,1.81 - 0.01 ,--,--,--,0,Y,Y,Y
Maternity Care: Elective Delivery or Early Induction Without Medical Indication at < 39 Weeks (Overuse),335,MIPS CQM,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Maternity Care: Postpartum Follow-up and Care Coordination,336,MIPS CQM,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
"Psoriasis: Tuberculosis (TB) Prevention for Patients with Psoriasis, Psoriatic Arthritis and Rheumatoid Arthritis on a Biological Immune Response Modifier",337,MIPS CQM,Process,Y,,76.975,3.69 - 27.57,27.58 - 62.33,62.34 - 90.46,90.47 - 99.99,--,--,--,100,N,N,N
HIV Viral Load Suppression,338,MIPS CQM,Outcome,Y,,81.717,28.21 - 50.19,50.2 - 77.96,77.97 - 86.59,86.6 - 97.48,97.49 - 99.99,--,--,100,N,N,Y
HIV Medical Visit Frequency,340,MIPS CQM,Process,Y,,69.282,9.49 - 40.65,40.66 - 51.88,51.89 - 70.2,70.21 - 92.12,92.13 - 99.99,--,--,100,N,N,Y
Pain Brought Under Control Within 48 Hours,342,MIPS CQM,Outcome,Y,,95.621,34.48 - 86.06,86.07 - 99.99,--,--,--,--,--,100,N,N,Y
"Rate of Carotid Artery Stenting (CAS) for Asymptomatic Patients, Without Major Complications (Discharged to Home by Post-Operative Day #2)",344,MIPS CQM,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Implantable Cardioverter-Defibrillator (ICD) Complications Rate,348,MIPS CQM,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Total Knee Replacement: Shared Decision-Making: Trial of Conservative (Non-surgical) Therapy,350,MIPS CQM,Process,Y,,96.086,22.86 - 89.52,89.53 - 99.64,99.65 - 99.99,--,--,--,--,100,Y,Y,Y
Total Knee Replacement: Venous Thromboembolic and Cardiovascular Risk Evaluation,351,MIPS CQM,Process,Y,,94.008,8.82 - 92.43,92.44 - 99.99,--,--,--,--,--,100,Y,Y,Y
Anastomotic Leak Intervention,354,MIPS CQM,Outcome,Y,,4.665,90.33 - 20.78,20.77 - 8.34,8.33 - 3.23,3.22 - 0.01,--,--,--,0,Y,Y,Y
Unplanned Reoperation within the 30 Day Postoperative Period,355,MIPS CQM,Outcome,Y,,3.563,82.57 - 10.15,10.14 - 4.61,4.6 -2.22,2.21 - 0.36,0.35 - 0.01,--,--,0,Y,Y,Y
Unplanned Hospital Readmission within 30 Days of Principal Procedure,356,MIPS CQM,Outcome,Y,,3.929,68.31 - 9.32,9.31 - 6.11,6.1 - 3.23,3.22 - 0.88,0.87 - 0.01,--,--,0,Y,Y,Y
Surgical Site Infection (SSI),357,MIPS CQM,Outcome,Y,,5.122,92.4 - 40.46,40.45 - 5.53,5.52 - 1.67,1.66 - 0.01,--,--,--,0,Y,Y,Y
Patient-Centered Surgical Risk Assessment and Communication,358,MIPS CQM,Process,Y,,73.794,0.32 - 4.82,4.83 - 54.81,54.82 - 97.35,97.36 - 99.99,--,--,--,100,Y,Y,Y
Optimizing Patient Exposure to Ionizing Radiation: Count of Potential High Dose Radiation Imaging Studies: Computed Tomography (CT) and Cardiac Nuclear Medicine Studies,360,MIPS CQM,Process,Y,,68.222,0.3 - 2.66,2.67 - 9.8,9.81 - 98.89,98.9 - 99.99,--,--,--,100,Y,Y,Y
Optimizing Patient Exposure to Ionizing Radiation: Appropriateness: Follow-up CT Imaging for Incidentally Detected Pulmonary Nodules According to Recommended Guidelines,364,MIPS CQM,Process,Y,,82.411,1.05 - 54.42,54.43 - 75.82,75.83 - 91.79,91.8 - 99.99,--,--,--,100,N,N,Y
Follow-Up Care for Children Prescribed ADHD Medication (ADD),366,eCQM,Process,Y,,29.041,1.74 - 10.43,10.44 - 15.28,15.29 - 26.4,26.41 - 35.44,35.45 - 49.47,49.48 - 74.41,74.42 - 90.53,>=90.54,N,N,N
Depression Remission at Twelve Months,370,MIPS CQM,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Depression Remission at Twelve Months,370,eCQM,Outcome,Y,,12.791,0.54 - 1.41,1.42 - 2.93,2.94 - 6.99,7 - 16.78,16.79 - 31.74,31.75 - 48.4,48.41 - 64.91,>=64.92,N,N,Y
Closing the Referral Loop: Receipt of Specialist Report,374,eCQM,Process,Y,,41.649,0.23 - 2.62,2.63 - 10.46,10.47 - 37.69,37.7 - 68.19,68.2 - 90.18,90.19 - 97.42,97.43 - 99.99,100,N,N,Y
Closing the Referral Loop: Receipt of Specialist Report,374,MIPS CQM,Process,Y,,74.453,1.13 - 5.89,5.9 - 51.75,51.76 - 96.19,96.2 - 99.99,--,--,--,100,Y,N,Y
Functional Status Assessment for Total Knee Replacement,375,eCQM,Process,Y,,27.037,0.33 - 1.48,1.49 - 3.11,3.12 - 14.99,15 - 45.63,45.64 - 75.13,75.14 - 85.54,85.55 - 98.15,>=98.16,N,N,Y
Functional Status Assessment for Total Hip Replacement,376,eCQM,Process,Y,,26.188,0.55 - 1.64,1.65 - 4.99,5 - 17.76,17.77 - 39.99,40 - 68.99,69 - 83.06,83.07 - 91.16,>=91.17,N,N,Y
Functional Status Assessments for Congestive Heart Failure,377,eCQM,Process,Y,,7.627,0.04 - 0.8,0.81 - 1.41,1.42 - 4.1,4.11 - 8.55,8.56 - 16.31,16.32 - 21.54,21.55 - 55.45,>=55.46,N,N,Y
Children Who Have Dental Decay or Cavities,378,eCQM,Outcome,Y,,0.448,5.57 - 2.19,2.18 - 1.37,1.36 - 0.36,0.35 - 0.01,--,--,--,0,Y,Y,Y
"Primary Caries Prevention Intervention as Offered by Primary Care Providers, including Dentists",379,eCQM,Process,Y,,4.415,0 - 0.05,0.06 - 0.3,0.31 - 2.4,2.41 - 5.53,5.54 - 11.22,11.23 - 18.21,18.22 - 25.52,>=25.53,N,N,N
Child and Adolescent Major Depressive Disorder (MDD): Suicide Risk Assessment,382,eCQM,Process,Y,,34.965,0.22 - 1.48,1.49 - 9.85,9.86 - 27.95,27.96 - 53.47,53.48 - 83.41,83.42 - 93.96,93.97 - 99.99,100,N,N,Y
Adherence to Antipsychotic Medications For Individuals with Schizophrenia,383,MIPS CQM,Intermediate Outcome,Y,,83.252,8.74 - 39.32,39.33 - 79.43,79.44 - 98.83,98.84 - 99.99,--,--,--,100,N,N,Y
Adult Primary Rhegmatogenous Retinal Detachment Surgery: No Return to the Operating Room Within 90 Days of Surgery,384,MIPS CQM,Outcome,Y,,97.615,67.73 - 91.45,91.46 - 99.99,--,--,--,--,--,100,Y,N,Y
Adult Primary Rhegmatogenous Retinal Detachment Surgery: Visual Acuity Improvement Within 90 Days of Surgery,385,MIPS CQM,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Amyotrophic Lateral Sclerosis (ALS) Patient Care Preferences,386,MIPS CQM,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Annual Hepatitis C Virus (HCV) Screening for Patients who are Active Injection Drug Users,387,MIPS CQM,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Cataract Surgery: Difference Between Planned and Final Refraction,389,MIPS CQM,Outcome,Y,,17.804,0.1 - 0.44,0.45 - 0.81,0.82 - 1.48,1.49 - 3.21,3.22 - 93.74,93.75 - 99.99,--,100,N,N,Y
Hepatitis C: Discussion and Shared Decision Making Surrounding Treatment Options,390,MIPS CQM,Process,Y,,80.178,4.64 - 37.9,37.91 - 69.46,69.47 - 99.99,--,--,--,--,100,Y,Y,Y
Follow-Up After Hospitalization for Mental Illness (FUH),391,MIPS CQM,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Cardiac Tamponade and/or Pericardiocentesis Following Atrial Fibrillation Ablation,392,MIPS CQM,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
"Infection within 180 Days of Cardiac Implantable Electronic Device (CIED) Implantation, Replacement, or Revision",393,MIPS CQM,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Immunizations for Adolescents,394,MIPS CQM,Process,Y,,15.884,0.55 - 1.99,2 - 4.27,4.28 - 13.78,13.79 - 23.8,23.81 - 36.41,36.42 - 46.36,46.37 - 60.94,>=60.95,N,N,N
Lung Cancer Reporting (Biopsy/Cytology Specimens),395,Medicare Part B Claims,Process,Y,,99.654,92.37 - 99.99,--,--,--,--,--,--,100,Y,Y,Y
Lung Cancer Reporting (Biopsy/Cytology Specimens),395,MIPS CQM,Process,Y,,98.452,53.87 - 99.61,99.62 - 99.99,--,--,--,--,--,100,Y,Y,Y
Lung Cancer Reporting (Resection Specimens),396,Medicare Part B Claims,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Lung Cancer Reporting (Resection Specimens),396,MIPS CQM,Process,Y,,99.063,70.78 - 99.99,--,--,--,--,--,--,100,Y,Y,Y
Melanoma Reporting,397,Medicare Part B Claims,Process,Y,,99.709,96.56 - 99.99,--,--,--,--,--,--,100,Y,Y,Y
Melanoma Reporting,397,MIPS CQM,Process,Y,,94.248,3.33 - 91.15,91.16 - 99.99,--,--,--,--,--,100,Y,Y,Y
Optimal Asthma Control,398,MIPS CQM,Outcome,Y,,71.421,0.68 - 20.38,20.39 - 44.4,44.41 - 84.57,84.58 - 99.99,--,--,--,100,N,N,Y
One-Time Screening for Hepatitis C Virus (HCV) for Patients at Risk,400,MIPS CQM,Process,Y,,25.373,0.13 - 0.37,0.38 - 1.26,1.27 - 3.89,3.9 - 46.37,46.38 - 87.67,87.68 - 99.99,--,100,N,N,N
Hepatitis C: Screening for Hepatocellular Carcinoma (HCC) in Patients with Cirrhosis,401,MIPS CQM,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Tobacco Use and Help with Quitting Among Adolescents,402,MIPS CQM,Process,Y,,91.638,24.3 - 77.34,77.35 - 90.37,90.38 - 97.05,97.06 - 99.91,99.92 - 99.99,--,--,100,Y,Y,N
Anesthesiology Smoking Abstinence,404,MIPS CQM,Intermediate Outcome,Y,,67.031,7.52 - 36.24,36.25 - 51.78,51.79 - 69.54,69.55 - 85.12,85.13 - 97.3,97.31 - 99.77,99.78 - 99.99,100,N,N,Y
Appropriate Follow-up Imaging for Incidental Abdominal Lesions,405,MIPS CQM,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Appropriate Follow-up Imaging for Incidental Abdominal Lesions,405,Medicare Part B Claims,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Appropriate Follow-up Imaging for Incidental Thyroid Nodules in Patients,406,Medicare Part B Claims,Process,Y,,4.598,81.33  - 31.57,31.56 - 4.88,4.87 - 0.01,--,--,--,--,0,Y,N,Y
Appropriate Follow-up Imaging for Incidental Thyroid Nodules in Patients,406,MIPS CQM,Process,Y,,5.641,66.08 - 29.91,29.9 - 16.92,16.91 - 4.53,4.52 - 0.01,--,--,--,0,Y,Y,Y
Opioid Therapy Follow-up Evaluation,408,MIPS CQM,Process,Y,,82.263,0.38 - 29.59,29.6 - 74.99,75 - 98.9,98.91 - 99.99,--,--,--,100,Y,Y,Y
Clinical Outcome Post Endovascular Stroke Treatment,409,MIPS CQM,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Psoriasis: Clinical Response to Systemic Medications,410,MIPS CQM,Outcome,Y,,66.917,1.81 - 15.02,15.03 - 42.9,42.91 - 76.71,76.72 - 96.6,96.61 - 99.99,--,--,100,N,N,Y
Documentation of Signed Opioid Treatment Agreement,412,MIPS CQM,Process,Y,,84.007,0.97 - 40.91,40.92 - 76.69,76.7 - 99.99,--,--,--,--,100,Y,Y,Y
Door to Puncture Time for Endovascular Stroke Treatment,413,MIPS CQM,Intermediate Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Evaluation or Interview for Risk of Opioid Misuse,414,MIPS CQM,Process,Y,,90.229,4.64 - 59.54,59.55 - 96.32,96.33 - 99.99,--,--,--,--,100,Y,Y,Y
Emergency Medicine: Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Aged 18 Years and Older,415,MIPS CQM,Efficiency,Y,,84.642,34.04 - 58.24,58.25 - 72.21,72.22 - 93.54,93.55 - 99.53,99.54 - 99.99,--,--,100,N,N,Y
Emergency Medicine: Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Aged 2 Through 17 Years,416,MIPS CQM,Efficiency,Y,,18.342,65.88 - 44.29,44.28 - 40.82,40.81 - 30.48,30.47 - 15.63,15.62 - 2.39,2.38 - 0.01,--,0,N,N,Y
Emergency Medicine: Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Aged 2 Through 17 Years,416,Medicare Part B Claims,Efficiency,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Osteoporosis Management in Women Who Had a Fracture,418,Medicare Part B Claims,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Osteoporosis Management in Women Who Had a Fracture,418,MIPS CQM,Process,Y,,26.366,0.52 - 2.03,2.04 - 3.3,3.31 - 9.51,9.52 - 39.11,39.12 - 89.64,89.65 - 99.99,--,100,N,N,N
Overuse of Imaging for the Evaluation of Primary Headache,419,Medicare Part B Claims,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Overuse of Imaging for the Evaluation of Primary Headache,419,MIPS CQM,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Varicose Vein Treatment with Saphenous Ablation: Outcome Survey,420,MIPS CQM,Patient Reported Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Appropriate Assessment of Retrievable Inferior Vena Cava (IVC) Filters for Removal,421,MIPS CQM,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Performing Cystoscopy at the Time of Hysterectomy for Pelvic Organ Prolapse to Detect Lower Urinary Tract Injury,422,MIPS CQM,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Performing Cystoscopy at the Time of Hysterectomy for Pelvic Organ Prolapse to Detect Lower Urinary Tract Injury,422,Medicare Part B Claims,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Perioperative Temperature Management,424,MIPS CQM,Outcome,Y,,96.934,48.43 - 91.68,91.69 - 98.88,98.89 - 99.84,99.85 - 99.99,--,--,--,100,Y,Y,Y
Photodocumentation of Cecal Intubation,425,Medicare Part B Claims,Process,N,,--,--,--,--,--,--,--,--,--,Y,Y,N
Photodocumentation of Cecal Intubation,425,MIPS CQM,Process,N,,--,--,--,--,--,--,--,--,--,Y,Y,N
Pelvic Organ Prolapse: Preoperative Screening for Uterine Malignancy,429,Medicare Part B Claims,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Pelvic Organ Prolapse: Preoperative Screening for Uterine Malignancy,429,MIPS CQM,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Prevention of Post-Operative Nausea and Vomiting (PONV) - Combination Therapy,430,MIPS CQM,Process,Y,,95.108,31.65 - 87.82,87.83 - 96.42,96.43 - 99.25,99.26 - 99.97,99.98 - 99.99,--,--,100,Y,Y,Y
Preventive Care and Screening: Unhealthy Alcohol Use: Screening & Brief Counseling,431,MIPS CQM,Process,Y,,68.429,0.22 - 11.37,11.38 - 44.87,44.88 - 81.56,81.57 - 97.16,97.17 - 99.99,--,--,100,N,N,N
Proportion of Patients Sustaining a Bladder Injury at the Time of any Pelvic Organ Prolapse Repair,432,MIPS CQM,Outcome,Y,,0.13,1.73 - 0.97,0.96 - 0.01,--,--,--,--,--,0,N,N,Y
Proportion of Patients Sustaining a Bowel Injury at the time of any Pelvic Organ Prolapse Repair,433,MIPS CQM,Outcome,Y,,0.12,1.12 - 1.02,1.01 - 0.41,0.4 - 0.01,--,--,--,--,0,N,N,Y
Proportion of Patients Sustaining a Ureter Injury at the Time of Pelvic Organ Prolapse Repair,434,MIPS CQM,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Quality of Life Assessment For Patients With Primary Headache Disorders,435,Medicare Part B Claims,Patient Reported Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Quality of Life Assessment For Patients With Primary Headache Disorders,435,MIPS CQM,Patient Reported Outcome,Y,,53.028,0.78 - 3.54,3.55 - 7.78,7.79 - 49.07,49.08 - 99.99,--,--,--,100,N,N,Y
Radiation Consideration for Adult CT: Utilization of Dose Lowering Techniques,436,Medicare Part B Claims,Process,Y,,94.857,2.36 - 90.17,90.18 - 98.48,98.49 - 99.89,99.9 - 99.99,--,--,--,100,Y,Y,N
Radiation Consideration for Adult CT: Utilization of Dose Lowering Techniques,436,MIPS CQM,Process,Y,,93.666,0.84 - 85.15,85.16 - 98.36,98.37 - 99.91,99.92 - 99.99,--,--,--,100,Y,Y,N
Rate of Surgical Conversion from Lower Extremity Endovascular Revascularization Procedure,437,Medicare Part B Claims,Outcome,Y,,1.031,3.91 - 3.58,3.57 - 2.95,2.94 - 2.03,2.02 - 0.01,--,--,--,0,N,N,Y
Rate of Surgical Conversion from Lower Extremity Endovascular Revascularization Procedure,437,MIPS CQM,Outcome,Y,,1.854,19.09 - 9.43,9.42 - 6.41,6.4 - 0.35,0.34 - 0.01 ,--,--,--,0,N,N,Y
Statin Therapy for the Prevention and Treatment of Cardiovascular Disease,438,eCQM,Process,Y,,65.812,3.54 - 42.19,42.2 - 60.55,60.56 - 69.82,69.83 - 77.12,77.13 - 83.5,83.51 - 86.2,86.21 - 95.54,>=95.55,N,N,N
Statin Therapy for the Prevention and Treatment of Cardiovascular Disease,438,MIPS CQM,Process,Y,,85.815,32.72 - 64.82,64.83 - 76.21,76.22 - 91.65,91.66 - 99.99,--,--,--,100,N,N,N
Age Appropriate Screening Colonoscopy,439,MIPS CQM,Efficiency,Y,,7.297,74.22 - 43.37,43.36 - 30.39,30.38 - 0.01,--,--,--,--,0,N,N,Y
Skin Cancer: Biopsy Reporting Time - Pathologist to Clinician,440,MIPS CQM,Process,Y,,95.447,6.94 - 92.08,92.09 - 99.15,99.16 - 99.99,--,--,--,--,100,Y,Y,Y
Ischemic Vascular Disease (IVD) All or None Outcome Measure (Optimal Control),441,MIPS CQM,Intermediate Outcome,Y,,53.782,1.7 - 20.82,20.83 - 40.4,40.41 - 58.97,58.98 - 69,69.01 - 77.36,77.37 - 81.72,81.73 - 87.39,>=87.4,N,N,Y
Non-Recommended Cervical Cancer Screening in Adolescent Females,443,MIPS CQM,Process,Y,,1.646,11.39 - 7.1,7.09 - 3.49,3.48 - 2.3,2.29 - 0.01,--,--,--,0,Y,N,Y
Medication Management for People with Asthma,444,MIPS CQM,Process,Y,,85.196,14.57 - 57.19,57.2 - 77.34,77.35 - 96.65,96.66 - 99.99,--,--,--,100,Y,Y,Y
Risk-Adjusted Operative Mortality for Coronary Artery Bypass Graft (CABG),445,MIPS CQM,Outcome,Y,,2.307,10.32 - 6.9,6.89 - 5.09,5.08 - 2.91,2.90 - 1.87,1.86 - 0.65,0.64 - 0.01,--,0,N,N,Y
Appropriate Workup Prior to Endometrial Ablation,448,MIPS CQM,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Trastuzumab Received By Patients With AJCC Stage I (T1c) - III And HER2 Positive Breast Cancer Receiving Adjuvant Chemotherapy,450,MIPS CQM,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
RAS (KRAS and NRAS) Gene Mutation Testing Performed for Patients with Metastatic Colorectal Cancer who receive Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody Therapy,451,MIPS CQM,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Patients with Metastatic Colorectal Cancer and RAS (KRAS or NRAS) Gene Mutation Spared Treatment with Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal Antibodies,452,MIPS CQM,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Percentage of Patients Who Died from Cancer Receiving Chemotherapy in the Last 14 Days of Life (lower score - better),453,MIPS CQM,Process,Y,,11.689,36.53 - 24.01,24 - 20.01,20 - 16.01,16 - 10.01,10 - 6.13,6.12 - 4.35,4.34 - 3.32,<= 3.31,N,N,Y
Percentage of Patients Who Died from Cancer Admitted to the Intensive Care Unit (ICU) in the Last 30 Days of Life (lower score - better),455,MIPS CQM,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Percentage of Patients Who Died from Cancer Admitted to Hospice for Less than 3 days (lower score - better),457,MIPS CQM,Outcome,Y,,10.828,24.9 - 20.52,20.51 - 18.78,18.77 - 14.96,14.95 - 10.01,10 - 5.51,5.5 - 3.54,3.53 - 2.89,<= 2.88,N,N,Y
All-cause Hospital Readmission,458,Administrative Claims,Outcome,TBD,,--,--,--,--,--,--,--,--,--,N,N,Y
Back Pain After Lumbar Discectomy/Laminectomy,459,MIPS CQM,Patient Reported Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Back Pain After Lumbar Fusion,460,MIPS CQM,Patient Reported Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Leg Pain After Lumbar Discectomy/Laminectomy,461,MIPS CQM,Patient Reported Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Bone Density Evaluation for Patients with Prostate Cancer and Receiving Androgen Deprivation Therapy,462,eCQM,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Prevention of Post-Operative Vomiting (POV) - Combination Therapy (Pediatrics),463,MIPS CQM,Process,Y,,95.88,58.58 - 91.17,91.18 - 95.69,95.7 - 98.56,98.57 - 99.99,--,--,--,100,Y,N,Y
Otitis Media with Effusion: Systemic Antimicrobials - Avoidance of Inappropriate Use,464,MIPS CQM,Process,Y,,91.999,70.38 - 80.63,80.64 - 88.12,88.13 - 94.79,94.8 - 98.16,98.17 - 99.99,--,--,100,Y,N,Y
Uterine Artery Embolization Technique: Documentation of Angiographic Endpoints and Interrogation of Ovarian Arteries,465,MIPS CQM,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Continuity of Pharmacotherapy for Opioid Use Disorder (OUD),468,MIPS CQM,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Functional Status After Lumbar Fusion,469,MIPS CQM,Patient Reported Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Functional Status After Primary Total Knee Replacement,470,MIPS CQM,Patient Reported Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Functional Status After Lumbar Discectomy/Laminectomy,471,MIPS CQM,Patient Reported Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Appropriate Use of DXA Scans in Women Under 65 Years Who Do Not Meet the Risk Factor Profile for Osteoporotic Fracture,472,eCQM,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Leg Pain After Lumbar Fusion,473,MIPS CQM,Patient Reported Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
HIV Screening,475,eCQM,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
International Prostate Symptom Score (IPSS) or American Urological Association-Symptom Index (AUA-SI) Change 6-12 Months After Diagnosis of Benign Prostatic Hyperplasia,476,eCQM,Patient Reported Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Multimodal Pain Management,477,MIPS CQM,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Functional Status Change for Patients with Neck Impairments,478,MIPS CQM,Patient Reported Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Asthma Assessment and Classification,AAAAI11,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Lung Function/Spirometry Evaluation,AAAAI12,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Asthma Control: Minimal Important Difference Improvement,AAAAI17,QCDR Measure,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Penicillin Allergy: Appropriate Removal or Confirmation,AAAAI18,QCDR Measure,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Asthma: Assessment of Asthma Control - Ambulatory Care Setting,AAAAI2,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Documentation of Clinical Response to Allergen Immunotherapy within One Year,AAAAI6,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Achievement of Projected Effective Dose of Standardized Allergens for Patient Treated With Allergen Immunotherapy for at Least One Year,AAAAI8,QCDR Measure,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Dermatitis - Improvement in Patient-Reported Itch Severity,AAD10,QCDR Measure,Patient Reported Outcome (PRO),N,,--,--,--,--,--,--,--,--,--,N,N,Y
Skin Cancer Surgery: Post-Operative Complications,AAD11,QCDR Measure,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Melanoma: - Appropriate Surgical Margins,AAD12,QCDR Measure,Intermediate Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Skin Cancer: Biopsy Reporting Time - Clinician to Patient,AAD6,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Psoriasis: Screening for Psoriatic Arthritis,AAD7,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Chronic Skin Conditions: Patient Reported Quality-of-Life,AAD8,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Psoriasis - Improvement in Patient-Reported Itch Severity,AAD9,QCDR Measure,Patient Reported Outcome (PRO),N,,--,--,--,--,--,--,--,--,--,N,N,Y
Falls screening (aggregation of AAN disease specific falls measures),AAN10,QCDR Measure,Process,Y,,23.928,0.2 - 2,2.01 - 4.31,4.32 - 15.25,15.26 - 36.04,36.05 - 64.86,64.87 - 69.84,69.85 - 84.67,>=84.68,N,N,Y
Quality of Life Outcome for Patients with Epilepsy,AAN12,QCDR Measure,Patient Reported Outcome (PRO),N,,--,--,--,--,--,--,--,--,--,N,N,Y
Querying and follow-up for co-morbid conditions of tic disorder (TD) and Tourette syndrome (TS),AAN20,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Quality of Life Outcome for Patients with Neurologic Conditions,AAN22,QCDR Measure,Patient Reported Outcome (PRO),N,,--,--,--,--,--,--,--,--,--,N,N,Y
Pediatric Medication reconciliation,AAN25,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Activity counseling for back pain,AAN26,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Falls plan of care,AAN27,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Diabetes/Pre-Diabetes Screening for Patients with DSP,AAN28,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Medication Prescribed For Acute Migraine Attack,AAN5,QCDR Measure,Process,Y,,63.033,8.97 - 39.71,39.72 - 53.32,53.33 - 65.61,65.62 - 75.99,76 - 83.68,83.69 - 87.4,87.41 - 91.99,>=92,N,N,N
Exercise and Appropriate Physical Activity Counseling for Patients with MS,AAN8,QCDR Measure,Process,Y,,73.063,17.25 - 38.78,38.79 - 56.89,56.9 - 78.44,78.45 - 93.52,93.53 - 99.99,--,--,100,N,N,N
Querying About Symptoms of Autonomic Dysfunction for Patients with Parkinson's Disease,AAN9,QCDR Measure,Process,Y,,61.51,0.82 - 3.59,3.6 - 27.48,27.49 - 78.66,78.67 - 94.38,94.39 - 98.64,98.65 - 99.99,--,100,N,N,N
Tympanostomy Tubes: Topical Ear Drop Monotherapy Acute Otorrhea,AAO12,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Bell's Palsy: Inappropriate Use of Magnetic Resonance Imaging or Computed Tomography Scan (Inverse Measure),AAO13,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Age-related Hearing Loss: Audiometric Evaluation,AAO16,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Age-related Hearing Loss: Advanced Diagnostic Imaging of Bilateral Presbycusis or Symmetric SNHL,AAO17,QCDR Measure,Process,Y,,98.946,88.59 - 97.65,97.66 - 98.62,98.63 - 99.99,--,--,--,--,100,N,N,Y
Tympanostomy Tubes: Hearing Test,AAO20,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Otitis Media with Effusion: Hearing Test for Chronic OME > 3 months,AAO21,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Allergic Rhinitis: Intranasal Corticosteroids or Oral Antihistamines,AAO23,QCDR Measure,Process,Y,,71.253,27.64 - 52.54,52.55 - 66.08,66.09 - 74.53,74.54 - 79.49,79.5 - 85.91,85.92 - 88.05,88.06 - 98.71,>=98.72,N,N,N
Allergic Rhinitis: Avoidance of Leukotriene Inhibitors,AAO24,QCDR Measure,Process,Y,,94.758,76.1 - 88.34,88.35 - 92.74,92.75 - 96.55,96.56 - 98.46,98.47 - 99.99,--,--,100,N,N,Y
Quality of Life for Patients with Neurotology Disorders,AAO29,QCDR Measure,Patient Reported Outcome (PRO),N,,--,--,--,--,--,--,--,--,--,N,N,Y
Otitis Media with Effusion (OME): Avoidance of Inappropriate Use of Medications,AAO31,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Standard BPPV Management,AAO32,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Dysphonia: Postoperative Laryngeal Examination,AAO34,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Benign Positional Paroxysmal Vertigo (BPPV): Dix-Hallpike and Canalith Repositioning,AAO35,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Tympanostomy Tubes: Resolution of Otitis Media with Effusion in Adults and Children ,AAO36,QCDR Measure,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Person-Centered Primary Care Measure Performance Measure (PCPCM-PM),ABFM10,QCDR Measure,Patient Reported Outcome (PRO),N,,--,--,--,--,--,--,--,--,--,N,N,Y
Patients Admitted to ICU who Have Care Preferences Documented,ABFM2,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Patients Treated with an Opioid Who Are Given a Bowel Regimen,ABFM3,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Palliative Care-Treatment Preferences,ABFM5,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Palliative Care Timely Dyspnea Screening & Treatment,ABFM6,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Pain Brought Under Control within the first three visits,ABFM7,QCDR Measure,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Measuring the Value-Functions of Primary Care: Provider Level Continuity Measure,ABFM9,QCDR Measure,Structure,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Planned use of difficult airway equipment,ABG16,QCDR Measure,Process,Y,,70.971,3.63 - 29.8,29.81 - 54.39,54.4 - 80.22,80.23 - 92.42,92.43 - 97.55,97.56 - 99.99,--,100,N,N,Y
Second provider present for induction/intubation of known or suspected difficult airway,ABG38,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Heart Failure: Patient Self Care Education,ACCPIN11,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Peripheral Artery Disease: Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk,ACCPIN7,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Hypertension Control (Stage 1 or 2),ACCPIN8,QCDR Measure,Intermediate Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Aged 18 Years and Older,ACEP19,QCDR Measure,Process,Y,,62.064,39.31 - 50.66,50.67 - 54.14,54.15 - 59.78,59.79 - 70.5,70.51 - 76.51,76.52 - 78.58,78.59 - 85.36,>=85.37,N,N,Y
Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Aged 2 Through 17 Years,ACEP20,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Coagulation Studies in Patients Presenting with Chest Pain with No Coagulopathy or Bleeding,ACEP21,QCDR Measure,Process,Y,,9.9,34.77 - 22.68,22.67 - 18.86,18.85 - 13.67,13.66 - 8.39,8.38 - 4.72,4.71 - 3.19,3.18 - 2.27,<= 2.26,N,N,Y
Appropriate Emergency Department Utilization of CT for Pulmonary Embolism,ACEP22,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Tobacco Use: Screening and Cessation Intervention for Patients with Asthma and COPD,ACEP25,QCDR Measure,Process,Y,,60.364,23.3 - 35.61,35.62 - 47.07,47.08 - 62.24,62.25 - 72.64,72.65 - 80.79,80.8 - 85.79,85.8 - 96.75,>=96.76,N,N,N
Sepsis Management: Septic Shock: Lactate Clearance Rate of ≥ 10%,ACEP30,QCDR Measure,Outcome,Y,,75.828,48.16 - 68.55,68.56 - 71.4,71.41 - 76.43,76.44 - 81.37,81.38 - 85.2,85.21 - 91.73,91.74 - 95.14,>=95.15,N,N,Y
Appropriate Foley catheter use in the emergency department,ACEP31,QCDR Measure,Process,Y,,87.278,49.68 - 63.47,63.48 - 83.44,83.45 - 91,91.01 - 99.9,99.91 - 99.99,--,--,100,N,N,Y
"Sepsis Management: Septic Shock: Lactate Level Measurement, Antibiotics Ordered, and Fluid Resuscitation",ACEP48,QCDR Measure,Process,Y,,76.699,11.62 - 60.04,60.05 - 73.03,73.04 - 81.78,81.79 - 87.19,87.2 - 92.29,92.3 - 93.23,93.24 - 94.99,>=95,N,N,N
ED Median Time from ED arrival to ED departure for discharged ED patients for Adult Patients,ACEP50,QCDR Measure,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
ED Median Time from ED arrival to ED departure for discharged ED patients for Pediatric Patients,ACEP51,QCDR Measure,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Appropriate Emergency Department Utilization of Lumbar Spine Imaging for Atraumatic Low Back Pain,ACEP52,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Appropriate Use of Imaging for Recurrent Renal Colic,ACEP53,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Adherence to Mohs Micrographic Surgery Appropriate Use Criteria,ACMS1,QCDR Measure,Efficiency and Cost/Resource Use,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Closing the Mohs Surgery Referral Loop: Transmission of Surgical Report,ACMS2,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Antibiotic Prophylaxis for High Risk Cardiac / Orthopedic Cases prior to Mohs micrographic surgery - Prevention of Overuse,ACMS3,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Surgical Site Infection Rate - Mohs Micrographic Surgery,ACMS4,QCDR Measure,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Documentation of High-Risk Squamous Cell Carcinoma Stage in Mohs Micrographic Surgery Record,ACMS5,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Management of perioperative anticoagulation with Mohs micrographic surgery,ACMS6,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Non-Opioid Pain Management Following Mohs micrographic surgery,ACMS7,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
High Risk Pneumococcal Vaccination,ACPGR1,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
"Tdap (Tetanus, Diphtheria, Acellular Pertussis) Vaccination",ACPGR2,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
High Intensity Statin for patients with NSTEMI-ACS,ACQR11,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
ABCDEF Bundle - Early mobility for ICU patients,ACQR12,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Sepsis: Hour One bundle,ACQR13,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Pneumonia: Use of CURB-65 for Risk Stratification in patient with CAP,ACQR15,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
COPD Exacerbation or CHF Exacerbation requiring Hospital Admission: Palliative Care Evaluation,ACQR16,QCDR Measure,Efficiency and Cost/Resource Use,N,,--,--,--,--,--,--,--,--,--,N,N,Y
COPD: Steroids for no more than 5 days in COPD Exacerbation,ACQR3,QCDR Measure,Efficiency and Cost/Resource Use,Y,,91.649,78.01 - 86.32,86.33 - 88.49,88.5 - 92.66,92.67 - 95.25,95.26 - 96.88,96.89 - 98.14,98.15 - 99.46,>=99.47,N,N,Y
Use of ACE-I or ARB and beta blockade in CHF,ACQR9,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Hepatitis B Safety Screening,ACR10,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Hydroxychloroquine Dosing,ACR11,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Disease Activity Measurement for Patients with PsA,ACR12,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Tuberculosis Test Prior to First Course Biologic Therapy,ACR13,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Gout: Serum Urate Target,ACR14,QCDR Measure,Intermediate Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Rheumatoid Arthritis Patients with Low Disease Activity or Remission,ACR9,QCDR Measure,Intermediate Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Report Turnaround Time: Radiography,ACRAD15,QCDR Measure,Outcome,Y,,2.903,30.84 - 10.2,10.1 - 8.01 ,8 - 3.01,3 - 1.01,1 - 0.01,--,--,0,N,N,Y
Report Turnaround Time: Ultrasound (Excluding Breast US),ACRAD16,QCDR Measure,Outcome,Y,,3.28,45.7 - 9.8,9.7 - 6.01,6 - 3.01,3 - 1.01,1 - 0.51,0.5 - 0.01,--,0,N,N,Y
Report Turnaround Time: MRI,ACRAD17,QCDR Measure,Outcome,Y,,6.775,33.17 - 19.01,19 - 15.01,15 - 8.01,8 - 5.01,5 - 2.01,2 - 1.01,1 - 0.01,0,N,N,Y
Report Turnaround Time: CT,ACRAD18,QCDR Measure,Outcome,Y,,2.539,33 - 11.01,11 - 6.01,6 - 2.01,2 - 1.01,1 - 0.01,--,--,0,N,N,Y
Report Turnaround Time: PET,ACRAD19,QCDR Measure,Outcome,Y,,17.076,88.9 - 60.76,60.75 - 41.51,41.5 - 20.76,20.75 - 8.51,8.5 - 4.01,4 - 1.01,1 - 0.01,0,N,N,Y
Report Turnaround Time: Mammography,ACRAD25,QCDR Measure,Outcome,Y,,31.253,220.3 - 83.01,83 - 49.51,49.5  - 23.01,23 - 11.01,11 - 3.01,3 - 0.01,--,0,N,N,Y
"Multi-strata weighted average for 3 CT Exam Types: Overall Percent of CT exams for which Dose Length Product is at or below the size-specific diagnostic reference level (for CT Abdomen-pelvis with contrast/single phase scan, CT Chest without contrast/single phase scan and CT Head/Brain without contrast/single phase scan)",ACRAD34,QCDR Measure,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Incidental Coronary Artery Calcification Reported on Chest CT,ACRAD36,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Interpretation of CT Pulmonary Angiography (CTPA) for Pulmonary Embolism,ACRAD37,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Use of Low Dose Cranial CT or MRI Examinations for Patients with Ventricular Shunts,ACRAD38,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Use of Low Dose CT Studies for Adults with Suspicion of Urolithiasis or Nephrolithiasis,ACRAD39,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Use of Structured Reporting in Prostate MRI,ACRAD40,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Use of Quantitative Criteria for Oncologic FDG PET Imaging,ACRAD41,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Surveillance Imaging for Liver Nodules <10mm in Patients at Risk for Hepatocellular Carcinoma (HCC),ACRAD42,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Ventral Hernia Repair: Pain and Functional Status Assessment,AHSQC10,QCDR Measure,Patient Reported Outcome (PRO),N,,--,--,--,--,--,--,--,--,--,N,N,Y
Abdominal Wall Reconstruction Surgical Site Occurrence Requiring Procedural Intervention within the 30 Day Postoperative Period,AHSQC6,QCDR Measure,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Hip Arthroplasty: Shared Decision-Making: Trial of Conservative (Non-surgical) Therapy,AJRR3,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Hip Arthroplasty: Venous Thromboembolic and Cardiovascular Risk Evaluation,AJRR4,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Coronary Artery Bypass Graft (CABG): Prolonged Intubation - Inverse Measure,AQI18,QCDR Measure,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Patient-Reported Experience with Anesthesia,AQI48,QCDR Measure,Patient Reported Outcome (PRO),Y,,94.548,86.04 - 91.14,91.15 - 92.74,92.75 - 94.93,94.94 - 96.18,96.19 - 97.6,97.61 - 99.51,99.52 - 99.99,100,N,N,Y
Adherence to Blood Conservation Guidelines for Cardiac Operations using Cardiopulmonary Bypass (CPB) - Composite,AQI49,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Team-Based Implementation of a Care-and-Communication Bundle for ICU Patients,AQI55,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Use of Neuraxial Techniques and/or Peripheral Nerve Blocks for Total Knee Arthroplasty (TKA),AQI56,QCDR Measure,Process,Y,,90.942,28.02 - 73.3,73.31 - 94.02,94.03 - 98.15,98.16 - 99.99,--,--,--,100,N,N,N
Safe Opioid Prescribing Practices,AQI57,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Infection Control Practices for Open Interventional Pain Procedures,AQI58,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Ambulatory Post-Discharge Patient Follow-Up,AQI61,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Obstructive Sleep Apnea: Patient Education,AQI62,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Avoidance of Cerebral Hyperthermia for Procedures Involving Cardiopulmonary Bypass,AQI65,QCDR Measure,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Consultation for Frail Patients,AQI67,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Obstructive Sleep Apnea: Mitigation Strategies,AQI68,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Stones: Repeat Shock Wave Lithotripsy (SWL) within 6 months of treatment,AQUA14,QCDR Measure,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Stones: Urinalysis documented 30 days before surgical stone procedures,AQUA15,QCDR Measure,Process,Y,,71.514,16 - 34.7,34.71 - 63.14,63.15 - 76.85,76.86 - 87.14,87.15 - 92.37,92.38 - 96.22,96.23 - 99.09,>=99.1,N,N,Y
Non-Muscle Invasive Bladder Cancer: Repeat Transurethral Resection of Bladder Tumor (TURBT) for T1 disease,AQUA16,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Non-Muscle Invasive Bladder Cancer: Initiation of BCG within 3 months of diagnosis of high-grade T1 bladder cancer and/or CIS,AQUA17,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Non-Muscle Invasive Bladder Cancer: Early surveillance cystoscopy within 4 months of initial diagnosis,AQUA18,QCDR Measure,Process,Y,,90.774,68.78 - 78.03,78.04 - 81.54,81.55 - 93.92,93.93 - 99.99,--,--,--,100,N,N,N
Diagnosis of Type of Azoospermia and Diagnostic Testing for Obstructive Azoospermia,AQUA19,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Appropriate Management of Obstructive Azoospermia,AQUA21,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Bone imaging and soft tissue imaging within 30 days (before or after) of diagnosis of metastatic CRPC,AQUA22,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Testosterone and PSA levels checked for CRPC patients,AQUA24,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Benign Prostate Hyperplasia Care: Benign Prostate Hyperplasia,AQUA26,QCDR Measure,Process,Y,,7.702,27.9 - 20.14,20.13 - 16.41,16.4 - 9.45,9.44 - 6.82,6.81 - 3.31,3.3 - 1.93,1.92 - 1.32,<= 1.31,N,N,Y
Hypogonadism: Laboratory evaluation conducted within 6 months of starting testosterone replacement,AQUA32,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Hospital admissions/complications within 30 days of TRUS Biopsy,AQUA8,QCDR Measure,Outcome,Y,,2.175,12.03 - 7.55,7.54 - 6.72,6.71 - 3.27,3.26 - 0.01,--,--,--,0,N,N,Y
Imaging Protocols for SPECT and PET MPI studies - Use of stress only protocol,ASNC19,QCDR Measure,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
SPECT-MPI study clinical utilization of Attenuation Correction image acquisition,ASNC23,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
SPECT-MPI effective dose less than or equal to 9 millisieverts as per ASNC guideline recommendations,ASNC28,QCDR Measure,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
SPECT and PET MPI study documentation of stress perfusion defects,ASNC29,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Patient Satisfaction with Information Provided during Breast Reconstruction,ASPS10,QCDR Measure,Patient Reported Outcome (PRO),N,,--,--,--,--,--,--,--,--,--,N,N,Y
Airway Assessment for patients undergoing Rhinoplasty,ASPS16,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Patient Satisfaction with Rhinoplasty Procedure,ASPS17,QCDR Measure,Patient Reported Outcome (PRO),N,,--,--,--,--,--,--,--,--,--,N,N,Y
Shared-decision making for post-operative management of discomfort following Rhinoplasty,ASPS18,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Continuation of Anticoagulation Therapy in the Office-based Setting for Reconstruction After Skin Cancer Resection Procedures,ASPS21,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Coordination of Care for Anticoagulated Patients Undergoing Reconstruction After Skin Cancer Resection,ASPS22,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Avoidance of Opioid Prescriptions for Reconstruction After Skin Cancer Resection,ASPS23,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Visits to the ER or Urgent Care Following Reconstruction After Skin Cancer Resection,ASPS24,QCDR Measure,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Avoidance of Post-operative Systemic Antibiotics for Office-based Reconstruction After Skin Cancer Resection Procedures,ASPS25,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Patient Satisfaction with Information Prior to Facial Reconstruction After Skin Cancer Resection Procedures,ASPS26,QCDR Measure,Patient Reported Outcome (PRO),N,,--,--,--,--,--,--,--,--,--,N,N,Y
Breast Reconstruction: Return to OR,ASPS5,QCDR Measure,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Rate of Blood Transfusion for Patients Undergoing Autologous Breast Reconstruction,ASPS7,QCDR Measure,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Coordination of Care for Patients Undergoing Breast Reconstruction,ASPS8,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Length of Stay Following Autologous Breast Reconstruction,ASPS9,QCDR Measure,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Blood Laboratory Samples for Potassium Determination with Hemolysis Drawn in ED,CAP10,QCDR Measure,Intermediate Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Accurate Human Epidermal Growth Factor Receptor 2 (HER2) Tumor Evaluation and Repeat Evaluation in Patients with Breast Carcinoma,CAP11,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Accurate Human Epidermal Growth Factor Receptor 2 (HER2) Tumor Evaluation and Repeat Evaluation in Patients with Gastroesophageal Adenocarcinoma,CAP12,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Anaplastic Lymphoma Kinase (ALK) Biomarker Testing to Inform Clinical Management and Treatment Decisions in Patients with Non-small Cell Lung Cancer,CAP13,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
BRAF Biomarker Testing to Inform Clinical Management and Treatment Decisions in Patients with Metastatic Colorectal Adenocarcinoma,CAP15,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Epidermal Growth Factor Receptor (EGFR) Biomarker Testing to Inform Clinical Management and Treatment Decisions in Patients with Non-small Cell Lung Cancer,CAP16,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
FMS-like Tyrosine 3-Internal Tandem Duplication (FLT3-ITD) Biomarker Testing to Inform Clinical Management and Treatment Decisions in Patients with Acute Myeloid Leukemia,CAP17,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Mismatch Repair (MMR) or Microsatellite Instability (MSI) Biomarker Testing to Inform Clinical Management and Treatment Decisions in Patients with Primary or Metastatic Colorectal Carcinoma,CAP18,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
ROS 1 Biomarker Testing to Inform Clinical Management and Treatment Decisions in Patients with Non-small Cell Lung Cancer,CAP19,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
High Risk HPV Testing and p16 Scoring in Surgical Specimens for Patients with Oropharyngeal Squamous Cell Carcinoma (OPSCC),CAP20,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
High Risk HPV Testing in Cytopathology Specimens for Patients with Oropharyngeal Squamous Cell Carcinoma (OPSCC),CAP21,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Turnaround Time (TAT) - Biopsies,CAP22,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Cancer Protocol Elements and Turnaround Time for Carcinoma and Carcinosarcoma of the Endometrium,CAP23,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Cancer Protocol Elements and Turnaround Time for Carcinoma of the Intrahepatic Bile Ducts,CAP24,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Cancer Protocol Elements and Turnaround Time for Carcinoma of the Pancreas,CAP25,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Cancer Protocol Elements and Turnaround Time for Hepatocellular Carcinoma,CAP26,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Cancer Protocol Elements and Turnaround Time for Invasive Carcinoma of Renal Tubular Origin,CAP27,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Helicobacter pylori Status and Turnaround Time,CAP28,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Turnaround Time (TAT) - Lactate,CAP29,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Urinary Bladder Biopsy Diagnostic Requirements For Appropriate Patient Management,CAP30,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
"Endometrial Carcinoma Testing for MMR, MSI, or Both",CAP31,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
"Prostate Cancer Gleason Pattern, Score, and Grade Group",CAP32,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Turnaround Time (TAT) - Troponin,CAP9,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Patient-Reported Pain and/or Function Improvement after Total Knee Arthroplasty,CCOME1,QCDR Measure,Patient Reported Outcome (PRO),N,,--,--,--,--,--,--,--,--,--,N,N,Y
Patient-Reported Pain and/or Function Improvement after Total Hip Arthroplasty,CCOME2,QCDR Measure,Patient Reported Outcome (PRO),N,,--,--,--,--,--,--,--,--,--,N,N,Y
Patient-Reported Pain and/or Function Improvement after Total Shoulder Arthroplasty,CCOME3,QCDR Measure,Patient Reported Outcome (PRO),N,,--,--,--,--,--,--,--,--,--,N,N,Y
Patient-Reported Pain and/or Function Improvement after ACLR Surgery,CCOME4,QCDR Measure,Patient Reported Outcome (PRO),N,,--,--,--,--,--,--,--,--,--,N,N,Y
Extent of Osteoarthritis Observed in Arthroscopic Partial Meniscectomy,CCOME5,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Patient-Reported Pain and/or Function Improvement after APM Surgery,CCOME6,QCDR Measure,Patient Reported Outcome (PRO),N,,--,--,--,--,--,--,--,--,--,N,N,Y
Adequate Off-loading of Diabetic Foot Ulcer at each visit,CDR1,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Diabetic Foot Ulcer (DFU) Healing or Closure,CDR2,QCDR Measure,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Adequate Compression at each visit for Patients with VLUs,CDR5,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Venous Leg Ulcer (VLU) outcome measure: Healing or Closure,CDR6,QCDR Measure,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Appropriate Use of hyperbaric oxygen therapy for patients with diabetic foot ulcers,CDR8,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Post operative hypocalcemia after thyroidectomy surgery,CESQIP1,QCDR Measure,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Pre operative ultrasound exam of patients with thyroid cancer,CESQIP3,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Related readmission for adrenal related problems,CESQIP5,QCDR Measure,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Avoid Head CT for Patients with Uncomplicated Syncope,ECPR39,QCDR Measure,Process,Y,,98.477,87.66 - 95.82,95.83 - 98.17,98.18 - 99.99,--,--,--,--,100,N,N,Y
Initiation of the Initial Sepsis Bundle,ECPR40,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Rh Status Evaluation and Treatment of Pregnant Women at Risk of Fetal Blood Exposure,ECPR41,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Avoidance of Creatine Kinase-MB (CK-MB) Testing for Non-traumatic Chest Pain,ECPR45,QCDR Measure,Process,Y,,93.29,54.87 - 79.14,79.15 - 95.03,95.04 - 98.16,98.17 - 99.42,99.43 - 99.93,99.94 - 99.99,--,100,N,N,Y
Avoidance of Opiates for Low Back Pain or Migraines,ECPR46,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Door to Diagnostic Evaluation by a Provider Within 30 Minutes - Urgent Care Patients,ECPR50,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Discharge Prescription of Naloxone after Opioid Poisoning or Overdose,ECPR51,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Appropriate Treatment of Psychosis and Agitation in the Emergency Department,ECPR52,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Clinician Reporting of Loss of Consciousness to State Department of Public Health or Department of Motor Vehicles,ECPR53,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Avoidance of Co-Prescribing of Opioid Analgesic and Benzodiazepine,ECPR54,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Avoidance of Long-Acting (LA) or Extended-Release (ER) Opiate Prescriptions and Opiate Prescriptions for Greater Than 3 Days Duration for Acute Pain,ECPR55,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Ultrasound Guidance for Peripheral Nerve Block with Patient Experience,EPREOP30,QCDR Measure,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Intraoperative Hypotension among Non-Emergent Noncardiac Surgical Cases,EPREOP31,QCDR Measure,Intermediate Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Review of Pain Status Assessment for Patients with Osteoarthritis,FORCE21,QCDR Measure,Patient Reported Outcome (PRO),N,,--,--,--,--,--,--,--,--,--,N,N,Y
Functional Status Change for Patients Post Stroke: Lower Body,FOTO2,QCDR Measure,Patient Reported Outcome (PRO),N,,--,--,--,--,--,--,--,--,--,N,N,Y
Functional Status Change for Patients Post Stroke: Upper Body,FOTO3,QCDR Measure,Patient Reported Outcome (PRO),N,,--,--,--,--,--,--,--,--,--,N,N,Y
Functional Status Changes for Patients with Upper or Lower Extremity Regional Swelling,FOTO4,QCDR Measure,Patient Reported Outcome (PRO) ,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Appropriate management of anticoagulation in the peri-procedural period rate - EGD,GIQIC10,QCDR Measure,Process,Y,,77.823,6.69 - 23.32,23.33 - 69.05,69.06 - 94.68,94.69 - 99.99,--,--,--,100,N,N,Y
Appropriate indication for colonoscopy,GIQIC12,QCDR Measure,Process,Y,,88.96,58.43 - 76.3,76.31 - 85.21,85.22 - 91.04,91.05 - 95.37,95.38 - 98.14,98.15 - 99.22,99.23 - 99.7,>=99.71,N,N,Y
Appropriate follow-up interval of 3 years recommended based on pathology findings from screening colonoscopy in average-risk patients,GIQIC15,QCDR Measure,Process,Y,,77.381,21.93 - 54.47,54.48 - 68.74,68.75 - 82.59,82.6 - 90.31,90.32 - 94.99,95 - 97.04,97.05 - 99.99,100,N,N,Y
Appropriate follow-up interval of 5 years for colonoscopies with findings of sessile serrated polyps < 10 mm without dysplasia,GIQIC17,QCDR Measure,Process,Y,,87.661,51.41 - 74.61,74.62 - 81.61,81.62 - 90.46,90.47 - 95.69,95.7 - 99.99,--,--,100,N,N,Y
Appropriate indication for esophagogastroduodenoscopy (EGD),GIQIC19,QCDR Measure,Process,Y,,61.251,15.55 - 26.88,26.89 - 37.52,37.53 - 60.08,60.09 - 90.69,90.7 - 96.79,96.8 - 98.98,98.99 - 99.99,100,N,N,Y
Appropriate follow-up interval of not less than 5 years for colonoscopies with findings of 1-2 tubular adenomas < 10 mm OR of 10 years for colonoscopies with only hyperplastic polyp findings in rectum or sigmoid,GIQIC21,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Screening Colonoscopy Adenoma Detection Rate,GIQIC22,QCDR Measure,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Venous Thromboembolism (VTE) Prophylaxis,HCPR14,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Physician's Orders for Life-Sustaining Treatment (POLST) Form,HCPR16,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Pressure Ulcers - Risk Assessment and Plan of Care,HCPR17,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Unintentional Weight Loss - Risk Assessment and Plan of Care,HCPR18,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
30 Day All Cause Readmit Rate for Discharged Inpatients,HCPR19,QCDR Measure,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Clostridium Difficile - Risk Assessment and Plan of Care,HCPR20,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Critical Care Transfer of Care - Use of Verbal Checklist or Protocol,HCPR22,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Mean Length of Stay for Inpatients - Pneumonia,HCPR3,QCDR Measure,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Mean Length of Stay for Inpatients - CHF,HCPR4,QCDR Measure,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Mean Length of Stay for Inpatients - COPD,HCPR5,QCDR Measure,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Functional Status Change for Patients With Upper-limb Functional Status Deficit,HM4,QCDR Measure,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Functional Status Change for Patients With Neck Functional Status Deficit,HM5,QCDR Measure,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Functional Status Change for Patients With Low Back Functional Status Deficit,HM6,QCDR Measure,Patient Reported Outcome (PRO),N,,--,--,--,--,--,--,--,--,--,N,N,Y
Functional Status Change for Patients with Vestibular Dysfunction,HM7,QCDR Measure,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Functional Status Change for Patients With Lower Extremity Functional Status Deficit,HM8,QCDR Measure,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Comprehensive TTE studies reporting a measured value of LVEF AND wall motion findings with LVEF < 50%,IGR1,QCDR Measure,Efficiency and Cost/Resource Use,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Transthoracic Echo (TTE) performance per ASE guidelines,IGR10,QCDR Measure,Efficiency and Cost/Resource Use,N,,--,--,--,--,--,--,--,--,--,N,N,Y
"Myocardial Perfusion Imaging (MPI), Transthoracic Echocardiography (TTE), or Stress Echocardiography studies meeting appropriate use criteria",IGR11,QCDR Measure,Efficiency and Cost/Resource Use,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Appropriate diagnosis verification and severity grading for valve disease through transthoracic echocardiography (TTE) quantitative parameters.,IGR12,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Appropriate Evaluation of Left Ventricular Structure and Systolic Function with Transthoracic Echocardiography (TTE) to Guide Heart Failure and Cardiomyopathy Management,IGR13,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
"Parameters in stress echocardiography dobutamine testing for low flow, low gradient aortic stenosis",IGR2,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Myocardial Perfusion Imaging (MPI) studies or Stress Echocardiography imaging studies not Equivocal,IGR4,QCDR Measure,Efficiency and Cost/Resource Use,N,,--,--,--,--,--,--,--,--,--,N,N,Y
"Myocardial Perfusion Imaging (MPI) studies, Transthoracic Echo (TTE), or Stress Echocardiography imaging studies reporting Left Ventricular Ejection Fraction",IGR5,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
SPECT-MPI or Stress Echocardiography imaging protocol selection for morbidly obese patients,IGR6,QCDR Measure,Efficiency and Cost/Resource Use,N,,--,--,--,--,--,--,--,--,--,N,N,Y
SPECT-MPI or Stress Echocardiography imaging studies with adequate exercise testing performed,IGR7,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
SPECT-MPI or Stress Echocardiography study utilization of exercise as a stressor,IGR8,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Stress echo performance for shortness of breath per ASE guidelines,IGR9,QCDR Measure,Efficiency and Cost/Resource Use,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Endothelial Keratoplasty - Post-operative improvement in best corrected visual acuity to 20/40 or better,IRIS1,QCDR Measure,Outcome,Y,,46.661,5.8 - 13.79,13.8 - 24.2,24.21 - 50.71,50.72 - 67.37,67.38 - 76.75,76.76 - 80.3,80.31 - 86.65,>=86.66,N,N,Y
Diabetic Macular Edema - Loss of Visual Acuity,IRIS13,QCDR Measure,Outcome,Y,,86.692,60.05 - 73.81,73.82 - 81.42,81.43 - 89.16,89.17 - 92.84,92.85 - 96.2,96.21 - 97.91,97.92 - 99.99,100,N,N,Y
Acute Anterior Uveitis: Post-treatment Grade 0 anterior chamber cells,IRIS17,QCDR Measure,Outcome,Y,,58.171,3.31 - 19.22,19.23 - 42.34,42.35 - 63.32,63.33 - 78.08,78.09 - 88.96,88.97 - 94.19,94.2 - 99.99,100,N,N,Y
Glaucoma - Intraocular Pressure Reduction,IRIS2,QCDR Measure,Intermediate Outcome,Y,,80.36,3.23 - 51.6,51.61 - 74.12,74.13 - 88.87,88.88 - 94.56,94.57 - 96.96,96.97 - 98.37,98.38 - 99.99,100,N,N,Y
Refractive Surgery: Patients with a postoperative uncorrected visual acuity (UCVA) of 20/20 or better within 30 days,IRIS23,QCDR Measure,Outcome,Y,,67.901,2.81 - 27.13,27.14 - 49.99,50 - 75.48,75.49 - 89.99,90 - 99.99,--,--,100,N,N,Y
Refractive Surgery: Patients with a postoperative correction within + or - 0.5 Diopter (D) of the intended correction,IRIS24,QCDR Measure,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Avoidance of Routine Antibiotic Use in Patients Before or After Intravitreal Injections,IRIS26,QCDR Measure,Efficiency and Cost/Resource Use,Y,,2.342,42.64 - 7.95,7.94 - 5.39,5.38 - 2.26,2.25 - 0.01,--,--,--,0,N,N,Y
Improvement of Macular Edema in Patients with Uveitis,IRIS35,QCDR Measure,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Endothelial Keratoplasty - Dislocation Requiring Surgical Intervention,IRIS38,QCDR Measure,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Intraocular Pressure Reduction Following Trabeculectomy or an Aqueous Shunt Procedure,IRIS39,QCDR Measure,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Improved visual acuity after epiretinal membrane treatment within 120 days,IRIS41,QCDR Measure,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Intraocular Pressure Reduction Following Laser Trabeculoplasty,IRIS43,QCDR Measure,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Visual Field Progression in Glaucoma,IRIS44,QCDR Measure,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Exudative Age-Related Macular Degeneration: Loss of Visual Acuity,IRIS45,QCDR Measure,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Evidence of anatomic closure of macular hole within 90 days after surgery as documented by OCT,IRIS46,QCDR Measure,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Adult Surgical Esotropia: Postoperative alignment,IRIS48,QCDR Measure,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Surgical Pediatric Esotropia: Postoperative alignment,IRIS49,QCDR Measure,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Surgery for Acquired Involutional Ptosis: Patients with an improvement of marginal reflex distance (MRD),IRIS5,QCDR Measure,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Amblyopia: Interocular visual acuity,IRIS50,QCDR Measure,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Acute Anterior Uveitis: Post-treatment visual acuity,IRIS51,QCDR Measure,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Post-operative opioid management following ocular surgery,IRIS52,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Chronic Anterior Uveitis - Post-treatment visual acuity,IRIS53,QCDR Measure,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Complications After Cataract Surgery,IRIS54,QCDR Measure,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Visual Acuity Improvement Following Cataract Surgery and Minimally Invasive Glaucoma Surgery,IRIS55,QCDR Measure,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Adult Diplopia: Improvement of ocular deviation or absence of diplopia or functional improvement,IRIS56,QCDR Measure,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Idiopathic Intracranial Hypertension: Improvement of mean deviation or stability of mean deviation,IRIS57,QCDR Measure,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Improved Visual Acuity after Vitrectomy for Complications of Diabetic Retinopathy within 120 Days,IRIS58,QCDR Measure,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Regaining Vision After Cataract Surgery,IRIS59,QCDR Measure,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Acquired Involutional Entropion: Normalized lid position after surgical repair,IRIS6,QCDR Measure,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Visual Acuity Improvement Following Cataract Surgery Combined with a Trabeculectomy or an Aqueous Shunt Procedure,IRIS60,QCDR Measure,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
"Failure to Progress (FTP): Proportion of patients failing to achieve a Minimal Clinically Important Difference (MCID) to indicate functional improvement in knee rehabilitation of patients with knee injury measured via their validated Knee Outcome Survey (KOS) score, or equivalent instrument which has undergone peer reviewed published validation and demonstrates a peer reviewed published MCID.",IROMS11,QCDR Measure,Patient Reported Outcome (PRO),N,,--,--,--,--,--,--,--,--,--,N,N,Y
"Failure to Progress (FTP): Proportion of patients failing to achieve a Minimal Clinically Important Difference (MCID) in improvement in pain score, measured via the Numeric Pain Rating Scale (NPRS), in revalidation patients with knee injury pain.",IROMS12,QCDR Measure,Patient Reported Outcome (PRO),N,,--,--,--,--,--,--,--,--,--,N,N,Y
"Failure to Progress (FTP): Proportion of patients not achieving a Minimal Clinically Important Difference (MCID) to indicate functional improvement in rehabilitation of patients with hip, leg or ankle injuries using the validated Lower Extremity Function Scale (LEFS) score, or equivalent instrument which has undergone peer reviewed published validation and demonstrates a peer reviewed published MCID.",IROMS13,QCDR Measure,Patient Reported Outcome (PRO),N,,--,--,--,--,--,--,--,--,--,N,N,Y
"Failure to Progress (FTP): Proportion of patients failing to achieve a Minimal Clinically Important Difference (MCID) in improvement in pain score, measured via the Numeric Pain Rating Scale (NPRS), in rehabilitation patients with hip, leg or ankle (lower extremity except knee) injury.",IROMS14,QCDR Measure,Patient Reported Outcome (PRO),N,,--,--,--,--,--,--,--,--,--,N,N,Y
Failure to Progress (FTP): Proportion of patients failing to achieve a Minimal Clinically Important Difference (MCID) to indicate functional improvement in rehabilitation of patients with neck pain/injury measured via the validated Neck Disability Index (NDI).,IROMS15,QCDR Measure,Patient Reported Outcome (PRO),N,,--,--,--,--,--,--,--,--,--,N,N,Y
"Failure to Progress (FTP): Proportion of patients failing to achieve a Minimal Clinically Important Difference (MCID) in improvement in pain score, measured via the Numeric Pain Rating Scale (NPRS), in rehabilitation patients with neck pain/injury.",IROMS16,QCDR Measure,Patient Reported Outcome (PRO),N,,--,--,--,--,--,--,--,--,--,N,N,Y
Failure to Progress (FTP): Proportion of patients failing to achieve a Minimal Clinically Important Difference (MCID) to indicate functional improvement in rehabilitation patients with low back pain measured via the validated Modified Low Back Pain Disability Questionnaire (MDQ) score.,IROMS17,QCDR Measure,Patient Reported Outcome (PRO),N,,--,--,--,--,--,--,--,--,--,N,N,Y
"Failure to Progress (FTP): Proportion of patients failing to achieve a Minimal Clinically Important Difference (MCID) in improvement in pain score, measured via the Numeric Pain Rating Scale (NPRS), in revalidation patients with low back pain.",IROMS18,QCDR Measure,Patient Reported Outcome (PRO),N,,--,--,--,--,--,--,--,--,--,N,N,Y
"Failure to Progress (FTP): Proportion of patients failing to achieve a Minimal Clinically Important Difference (MCID) to indicate functional improvement in rehabilitation of patients with arm, shoulder, and hand injury measured via the validated Disability of Arm Shoulder and Hand (DASH) score, Quick Disability of Arm Shoulder and Hand (QDASH) score, or equivalent instrument which has undergone peer reviewed published validation and demonstrates a peer reviewed published MCID.",IROMS19,QCDR Measure,Patient Reported Outcome (PRO),N,,--,--,--,--,--,--,--,--,--,N,N,Y
"Failure to Progress (FTP): Proportion of patients failing to achieve a Minimal Clinically Important Difference (MCID) in improvement in pain score, measured via the Numeric Pain Rating Scale (NPRS),  in rehabilitation patients with arm, shoulder, or hand injury.",IROMS20,QCDR Measure,Patient Reported Outcome (PRO),N,,--,--,--,--,--,--,--,--,--,N,N,Y
Anxiety Screening,MBHR1,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Symptom Improvement in adults with ADHD,MBHR10,QCDR Measure,Patient Reported Outcome (PRO),N,,--,--,--,--,--,--,--,--,--,N,N,Y
Anxiety Response at 6-months,MBHR2,QCDR Measure,Patient Reported Outcome (PRO),N,,--,--,--,--,--,--,--,--,--,N,N,Y
Pain Interference Response utilizing PROMIS,MBHR3,QCDR Measure,Patient Reported Outcome (PRO),N,,--,--,--,--,--,--,--,--,--,N,N,Y
Social Role Functioning Outcome utilizing PROMIS,MBHR4,QCDR Measure,Patient Reported Outcome (PRO),N,,--,--,--,--,--,--,--,--,--,N,N,Y
Screening and monitoring for psychosocial problems among children and youth,MBHR5,QCDR Measure,Patient Reported Outcome (PRO),N,,--,--,--,--,--,--,--,--,--,N,N,Y
Sleep Quality Screening and Sleep Response at 3-months,MBHR6,QCDR Measure,Patient Reported Outcome (PRO),N,,--,--,--,--,--,--,--,--,--,N,N,Y
Posttraumatic Stress Disorder (PTSD) Screening and Outcome Assessment,MBHR7,QCDR Measure,Patient Reported Outcome (PRO),N,,--,--,--,--,--,--,--,--,--,N,N,Y
Alcohol Use Disorder Outcome Response,MBHR8,QCDR Measure,Patient Reported Outcome (PRO),N,,--,--,--,--,--,--,--,--,--,N,N,Y
Outcome monitoring of ADHD functional impairment in children and youth,MBHR9,QCDR Measure,Patient Reported Outcome (PRO),N,,--,--,--,--,--,--,--,--,--,N,N,Y
Use of Capnography for Non-Operating Room Anesthesia,MEDNAX53,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Labor Epidural Failure when Converting from Labor Analgesia to Cesarean Section Anesthesia,MEDNAX54,QCDR Measure,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Use of ASPECTS (Alberta Stroke Program Early CT Score) for non-contrast CT Head performed for suspected acute stroke.,MEDNAX55,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
"Use of a ""PEG Test"" to Manage Patients Receiving Opioids",MEDNAX56,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Heel Pain Treatment Outcomes for Pediatric Patients,MEX2,QCDR Measure,Patient Reported Outcome (PRO),N,,--,--,--,--,--,--,--,--,--,N,N,Y
Bunion Outcome - Adult and Adolescent,MEX4,QCDR Measure,Patient Reported Outcome (PRO),Y,,24.973,0.89 - 2.21,2.22 - 4.69,4.7 - 18.87,18.88 - 33.54,33.55 - 68.03,68.04 - 76.8,76.81 - 95.45,>=95.46,N,N,Y
Hammer Toe Outcome,MEX5,QCDR Measure,Patient Reported Outcome (PRO),Y,,25.046,0.85 - 1.78,1.79 - 4.67,4.68 - 15.37,15.38 - 31.68,31.69 - 67.7,67.71 - 78.94,78.95 - 93.03,>=93.04,N,N,Y
Screening Coronary Calcium Scoring for Cardiovascular Risk Assessment Including Coronary Artery Calcification Regional Distribution Scoring,MSN13,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Screening Abdominal Aortic Aneurysm Reporting with Recommendations,MSN14,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Use of Thyroid Imaging Reporting & Data System (TI-RADS) in Final Report to Stratify Thyroid Nodule Risk,MSN15,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
CollaboRATE Shared Decision Making Score,MUSE1,QCDR Measure,Patient Engagement/Experience,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Prostate Cancer: Confirmation Testing in low risk AS eligible patients,MUSIC10,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Prostate Cancer: Follow-Up Testing for patients on active surveillance for at least 30 months,MUSIC11,QCDR Measure,Process,Y,,16.036,4.03 - 4.55,4.56 - 5.86,5.87 - 12.36,12.37 - 23,23.01 - 29.58,29.59 - 33.13,33.14 - 49.24,>=49.25,N,N,N
Kidney Stones: ED visit within 30 days of ureteroscopy,MUSIC12,QCDR Measure,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Kidney Stones: Antibiotics should not be provided at the time of SWL,MUSIC13,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Kidney Stones: SWL in patients with largest renal stone > 2 cm or lower pole stone > 1 cm,MUSIC15,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Kidney Stones: Opioid utilization after ureteroscopy and shockwave lithotripsy ,MUSIC17,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Kidney Stones: Alpha-blockers at discharge for patients undergoing ureteroscopy or shockwave lithotripsy,MUSIC18,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Kidney Stones: Readmission within 30 days of ureteroscopy,MUSIC19,QCDR Measure,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Prostate Cancer: Complications within 30 days of radical prostatectomy,MUSIC20,QCDR Measure,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Prostate Cancer: Opioid utilization after radical prostatectomy,MUSIC21,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Prostate Cancer: Urinary continence at 12 months post-radical prostatectomy,MUSIC22,QCDR Measure,Patient Reported Outcome (PRO),N,,--,--,--,--,--,--,--,--,--,N,N,Y
Renal Mass: Documentation of the RENAL score for patients with small renal mass diagnoses,MUSIC23,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Kidney Stones: Post-ureteroscopy and shockwave lithotripsy imaging for any stones,MUSIC24,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Renal Mass: ED visit or Readmission within 30 days of radical nephrectomy,MUSIC25,QCDR Measure,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Renal Mass: ED Visit or Readmission within 30 days of partial nephrectomy,MUSIC26,QCDR Measure,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Prostate Cancer: Active Surveillance/Watchful Waiting for Low Risk Prostate Cancer Patients,MUSIC4,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Prostate Cancer: Radical Prostatectomy Cases LOS,MUSIC5,QCDR Measure,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Cognitive Assessment and Plan of Care for Home-Based Primary Care and Palliative Care Patients,NHBPC14,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Functional Assessment (Basic and Instrumental Activities of Daily Living [ADL]) for Home-Based Primary Care and Palliative Care Patients,NHBPC15,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Screening for Depression and Follow-up Plan in Home-Based Primary Care and Palliative Care Patients,NHBPC17,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Delirium Assessment in Home-Based Primary Care and Palliative Care Patients: Medication List Reviewed & Offending Medications Discontinued,NHBPC18,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Alcohol Problem Use Assessment & Brief Intervention for Home-Based Primary Care and Palliative Care Patients,NHBPC2,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Referral to Hospice for Appropriate Home-Based Primary Care and Palliative Care Patients,NHBPC9,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Repeat screening or surveillance colonoscopy recommended within one year due to inadequate/poor bowel preparation,NHCR4,QCDR Measure,Process,Y,,44.026,3.41 - 7.74,7.75 - 18.5,18.51 - 39.27,39.28 - 65.15,65.16 - 88.74,88.75 - 95.83,95.84 - 99.99,100,N,N,Y
CHANGE IN PATIENT REPORTED QUALITY OF LIFE FOLLOWING EPIDURAL LYSIS OF ADHESIONS,NIPM18,QCDR Measure,Patient Reported Outcome (PRO),N,,--,--,--,--,--,--,--,--,--,N,N,Y
CHANGE IN PATIENT REPORTED QUALITY OF LIFE AND FUNCTIONAL STATUS FOLLOWING MEDIAL BRANCH RADIOFREQUENCY ABLATION,NIPM19,QCDR Measure,Patient Reported Outcome (PRO),N,,--,--,--,--,--,--,--,--,--,N,N,Y
CHANGE IN PATIENT REPORTED PAIN AND FUNCTIONAL STATUS FOLLOWING SPINAL CORD STIMULATOR IMPLANTATION,NIPM20,QCDR Measure,Patient Reported Outcome (PRO),N,,--,--,--,--,--,--,--,--,--,N,N,Y
CHANGE IN PATIENT REPORTED QUALITY OF LIFE FOLLOWING EPIDURAL CORTICOSTEROID INJECTION,NIPM22,QCDR Measure,Patient Reported Outcome (PRO),N,,--,--,--,--,--,--,--,--,--,N,N,Y
CHANGE IN PATIENT REPORTED QUALITY OF LIFE FOLLOWING MAJOR JOINT CORTICOSTEROID INJECTION,NIPM23,QCDR Measure,Patient Reported Outcome (PRO),N,,--,--,--,--,--,--,--,--,--,N,N,Y
CHANGE IN PATIENT REPORTED QUALITY OF LIFE FOLLOWING INTRATHECAL PUMP IMPLANTATION,NIPM24,QCDR Measure,Patient Reported Outcome (PRO),N,,--,--,--,--,--,--,--,--,--,N,N,Y
CHANGE IN PATIENT REPORTED QUALITY OF LIFE FOLLOWING INTERSPINOUS INDIRECT DECOMPRESSION (SPACER),NIPM25,QCDR Measure,Patient Reported Outcome (PRO),N,,--,--,--,--,--,--,--,--,--,N,N,Y
Notification to the ordering provider requesting myoglobin or CK-MB in the diagnosis of suspected acute myocardial infarction (AMI),NPQR1,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Rate of communicating results of an amended report with a major discrepancy to the responsible provider,NPQR11,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Rate of notification to clinical provider of a new diagnosis of malignancy,NPQR13,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Non-small cell lung carcinoma (NSCLC) ancillary biomarker testing status and turnaround time (TAT) from point of specimen accession date to ancillary biomarker testing completion and reporting date should be ≤ 10 days ,NPQR15,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Notification to the provider ordering repeat blood chemistry panels in clinically stable patients within four days.,NPQR16,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Notification to the provider ordering repeat C. difficile stool toxin testing within seven days,NPQR17,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Notification to the provider ordering repeat CBCs in clinically stable patients within four days,NPQR18,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Notification to the provider ordering repeat Hepatitis C serology testing on a patient with previously positive results,NPQR19,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Notification to the ordering provider requesting thyroid screening tests other than only a Thyroid Stimulating Hormone (TSH) test in the initial screening of a patient with a suspected thyroid disorder,NPQR2,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Notification to the ordering provider requesting amylase testing in the diagnosis of suspected acute pancreatitis,NPQR3,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Time interval: critical value reporting for chemistry,NPQR4,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Time interval: critical value reporting for cerebrospinal fluid - white blood cell (CSF - WBC),NPQR5,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Time interval: critical value reporting for toxicology,NPQR6,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Time interval: critical value reporting for troponin,NPQR7,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Quality of Life - Physical Health Outcomes by Oberd,OBERD32,QCDR Measure,Patient Reported Outcome (PRO),N,,--,--,--,--,--,--,--,--,--,N,N,Y
Appropriate non-invasive arterial testing for patients with intermittent claudication who are undergoing a LE peripheral vascular intervention,OEIS6,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Structured Walking Program Prior to Intervention for Claudication,OEIS7,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Use of ultrasound guidance for vascular access,OEIS8,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Patient Reported Health-Related Quality of Life (HRQoL) during Treatment for Advanced Cancer,ONSQIR21,QCDR Measure,Patient Reported Outcome (PRO),N,,--,--,--,--,--,--,--,--,--,N,N,Y
PCR Test with MR2 or greater result (BCR-ABL1 transcript level <= 1% [IS]) for patients receiving TKI for at least 6 months for Chronic Myelogenous Leukemia,ONSQIR22,QCDR Measure,Intermediate Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Assessment for and management of immune-related adverse events during cancer treatment with checkpoint inhibitors (ICPi),ONSQIR23,QCDR Measure,Intermediate Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Oncology: Advance Care Planning in Metastatic Cancer Patients,PIMSH1,QCDR Measure,Patient Engagement/Experience,Y,,29.476,0.22 - 0.65,0.66 - 2.11,2.12 - 20.95,20.96 - 48.85,48.86 - 81.39,81.4 - 88.66,88.67 - 92.96,>=92.97,N,N,Y
Oncology: Hepatitis B Serology Testing and Prophylactic Treatment Prior to receiving anti-CD20 targeting drugs,PIMSH10,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
"Oncology: Utilization of PET, PET/CT, or CT scans for Breast Cancer stage 0, I, or II at any time during the course of evaluation and treatment",PIMSH11,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Oncology: Patient-Reported Pain Improvement,PIMSH4,QCDR Measure,Patient Reported Outcome (PRO),N,,--,--,--,--,--,--,--,--,--,N,N,Y
Oncology: Mutation Testing for Lung Cancer Completed Prior to Start of Targeted Therapy,PIMSH8,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Oncology: Supportive Care Drug Utilization in Last 14 Days of Life,PIMSH9,QCDR Measure,Efficiency and Cost/Resource Use,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Appropriate Documentation of a Malnutrition Diagnosis,PINC55,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Assessment of Nutritionally At-Risk Patients for Malnutrition and Development of Nutrition Recommendations/Interventions by a Registered Dietitian Nutritionist ,PINC56,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Combination chemotherapy received within 4 months of diagnosis by women under 70 with AJCC stage IA (T1c) to III ER/PR negative breast cancer,QOPI11,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
GCSF administered to patients who received chemotherapy for metastatic cancer (Lower Score -Better),QOPI15,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Oncology: Treatment Summary Communication - Radiation Oncology,QOPI21,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
External Beam Radiotherapy for Bone Metastases,QOPI22,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Concurrent Chemoradiation for Patients with a Diagnosis of Stage IIIB NSCLC,QOPI23,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Hypofractionization Whole Breast Irradiation,QOPI24,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Moderate Hypofractionization for Prostate Cancer,QOPI25,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Sentinel Lymph Node (SLN) Biopsies for Patients with AJCC T1b-T4 Melanoma,QOPI26,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Appropriate Antiemetic Therapy for High- and Moderate-Emetic Risk Antineoplastic Agents,QOPI27,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Chemotherapy administered to patients with metastatic solid tumor with performance status of ECOG 3 or 4; KPS 10 - 40; or undocumented (Lower Score - Better),QOPI5,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Central Line Ultrasound Guidance,QUANTUM31,QCDR Measure,Process,Y,,88.398,15.27 - 59.31,59.32 - 85.23,85.24 - 98.44,98.45 - 99.99,--,--,--,100,N,N,Y
CKD 3-5 Patients Seen at the Recommended Frequency Levels,RCOIR1,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Upper Extremity Edema Improvement,RCOIR10,QCDR Measure,Patient Reported Outcome (PRO),Y,,60.835,19.6 - 36.61,36.62 - 51.78,51.79 - 60.92,60.93 - 73.92,73.93 - 78.93,78.94 - 82.84,82.85 - 89.2,>=89.21,N,N,Y
Tunneled Hemodialysis Catheter Success,RCOIR12,QCDR Measure,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
CKD 3-5 Patients with a Urine ACR or Urine PCR Lab Test,RCOIR3,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
End Stage Renal Disease (ESRD) Initiation of Home Dialysis or Self-Care,RCOIR5,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Improved Access Site Bleeding,RCOIR7,QCDR Measure,Outcome,Y,,70.13,22.49 - 48.94,48.95 - 59.33,59.34 - 73.45,73.46 - 85.89,85.9 - 90.46,90.47 - 93.42,93.43 - 94.76,>=94.77,N,N,Y
Heel Pain Treatment Outcomes for Adults,REGCLR1,QCDR Measure,Patient Reported Outcome (PRO),N,,--,--,--,--,--,--,--,--,--,N,N,Y
Angiotensin Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy,RPAQIR1,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Rate of Timely Documentation Transmission to Dialysis Unit/Referring Physician,RPAQIR13,QCDR Measure,Process,Y,,79.788,1.96 - 69.24,69.25 - 76.88,76.89 - 83.79,83.8 - 88.18,88.19 - 99.2,99.21 - 99.97,99.98 - 99.99,100,N,N,Y
Arteriovenous Graft Thrombectomy Success Rate,RPAQIR14,QCDR Measure,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Arteriovenous Fistulae Thrombectomy Success Rate,RPAQIR15,QCDR Measure,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Peritoneal Dialysis Catheter Success Rate,RPAQIR16,QCDR Measure,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Peritoneal Dialysis Catheter Exit Site Infection Rate,RPAQIR17,QCDR Measure,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Advance Directives Completed,RPAQIR18,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Arteriovenous Fistula Rate,RPAQIR4,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Transplant Referral,RPAQIR5,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Advance Care Planning (Pediatric Kidney Disease),RPAQIR9,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Timely Gastrointestinal Radiology Result Notification,SMD26,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Timely Pathology Peer Review,SMD32,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Timely Radiology Peer Review,SMD33,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Timely Notification of Diagnostic Exams That Require Follow-up,SMD36,QCDR Measure,Intermediate Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Timely Aorta Result Notification,SMD37,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Timely Vascular Ultrasound Result Notification,SMD38,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Effective Image Guided Biopsies,SMD39,QCDR Measure,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Optimized Thrombolysis in Ischemic Stroke,SMD40,QCDR Measure,Intermediate Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Elimination of narcotic medication use following spinal fusion surgery,SPINETRACK10,QCDR Measure,Patient Reported Outcome (PRO),N,,--,--,--,--,--,--,--,--,--,N,N,Y
Percent of patients meeting SCB thresholds for back or neck pain,SPINETRACK4,QCDR Measure,Patient Reported Outcome (PRO),N,,--,--,--,--,--,--,--,--,--,N,N,Y
Percent of patients meeting SCB thresholds for leg or arm pain,SPINETRACK5,QCDR Measure,Patient Reported Outcome (PRO),N,,--,--,--,--,--,--,--,--,--,N,N,Y
Percent of patients meeting SCB thresholds for pain-related disability (ODI/NDI),SPINETRACK6,QCDR Measure,Patient Reported Outcome (PRO),N,,--,--,--,--,--,--,--,--,--,N,N,Y
Infection in spinal fusion surgery,SPINETRACK7,QCDR Measure,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Patient satisfaction following spinal fusion surgery,SPINETRACK8,QCDR Measure,Patient Reported Outcome (PRO),N,,--,--,--,--,--,--,--,--,--,N,N,Y
Unplanned hospital readmission following spinal fusion surgery,SPINETRACK9,QCDR Measure,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Prolonged Length of Stay Following Coronary Artery Bypass Grafting,STS1,QCDR Measure,Outcome,Y,,4.596,16.58 - 10.84,10.83 - 9.2,9.19 - 6.72,6.71 - 3.71,3.7 - 2.17,2.16 - 0.2,0.19 - 0.01,0,N,N,Y
Patient Centered Surgical Risk Assessment and Communication for Cardiac Surgery,STS7,QCDR Measure,Process,Y,,52.346,0.6 - 1.99,2 - 5.89,5.9 - 56.51,56.52 - 92.1,92.11 - 98.89,98.9 - 99.99,--,100,N,N,Y
Ankylosing Spondylitis: Controlled Disease,UREQA1,QCDR Measure,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Ankylosing Spondylitis: Appropriate Pharmacologic Therapy,UREQA2,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Folic or Folinic Acid Therapy for Patients Treated with Methotrexate,UREQA4,QCDR Measure,Process,Y,,87.218,46.81 - 69.75,69.76 - 83.57,83.58 - 93.29,93.3 - 96.19,96.2 - 98.51,98.52 - 99.82,99.83 - 99.98,>=99.99,N,N,N
Patient Reported Nutritional Assessment in Patients with Wounds and Ulcers,USWR22,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Non Invasive Arterial Assessment of patients with lower extremity wounds or ulcers for determination of healing potential,USWR23,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Patient Reported Experience of Care: Wound Outcome,USWR24,QCDR Measure,Patient Reported Outcome (PRO),N,,--,--,--,--,--,--,--,--,--,N,N,Y
Pressure Ulcer* (PU) Healing or Closure for ulcers on the torso (body),USWR25,QCDR Measure,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Patient Reported Outcome of late effects of radiation symptoms following treatment with Hyperbaric Oxygen Therapy (HBOT),USWR26,QCDR Measure,Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Assessment of Nutritionally At-Risk Patients for Malnutrition and Development of Nutrition Recommendations/Interventions by a Registered Dietitian Nutritionist,USWR27,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Obtaining Preoperative Nutritional Recommendations from a Registered Dietitian Nutritionist (RDN) in Nutritionally At-Risk Surgical Patients,USWR28,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Diabetes Care All or None Outcome Measure: Optimal Control,WCHQ10,QCDR Measure,Intermediate Outcome,N,,--,--,--,--,--,--,--,--,--,N,N,Y
Screening For Osteoporosis,WCHQ15,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Controlling High Blood Pressure: eGFR Test Annually,WCHQ32,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N
Diabetes Care All or None Process Measure: Optimal Testing,WCHQ9,QCDR Measure,Process,N,,--,--,--,--,--,--,--,--,--,N,N,N